Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-2004

Ionizing Radiation and Endostatin Gene Therapy Against Lung
Tumor
Xian Luo

Follow this and additional works at: https://scholarsrepository.llu.edu/etd
Part of the Medical Biochemistry Commons, Molecular Genetics Commons, and the Neoplasms
Commons

Recommended Citation
Luo, Xian, "Ionizing Radiation and Endostatin Gene Therapy Against Lung Tumor" (2004). Loma Linda
University Electronic Theses, Dissertations & Projects. 1025.
https://scholarsrepository.llu.edu/etd/1025

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. For more information, please contact scholarsrepository@llu.edu.

UNIVERSITY LIBRARY
LOMA UNDA, CALIFORNIA
LOMA LINDA UNIVERSITY
Graduate School

Ionizing Radiation and Endostatin Gene Therapy Against Lung Tumor
by
Xian Luo

A Dissertation Submitted in Partial Fulfillment of the
Requirements for the Degree of Doctor of Philosophy in
Biochemistry

June 2004

©2004

Xian Luo
All Rights Reserved

Each person whose signature appears below certifies that this dissertation in his or her
opinion is adequate, in scope and quality, as a dissertation for the degree of Doctor of
Philosophy.

\

< .0: )

J .

,Chairperson
Daila S. Gridley, Professor of Microbiology & Molecular Genetics and Radiation
Medicine
"

X

Penelope Duerksen-Hughes, Associate Professor of Biochemistry

Istvan Fodor, Professor of Microbiology & Molecular Genetics

E. Clifford fjrf
Biochemistry

ann,/Graduate Program Coordinator, Associate Professor of

LawreMe C. Sowers, Professor and Chair of Department of Biochemistry and
Microbiology

m

ACKNOWLEDGEMENTS

First of all, I would like to thank God for his mercy and grace to all people
regardless of races, nationalities, and sexes... And no matter if we are young or old, rich
or poor, we all have equal opportunity to be with Jesus Christ. I am drawn by love to
share the good news of God expressed through the life and gospel of Jesus Christ and to
hasten His return.
I would also thank those individuals, who have been involved in working together
with me to the completion of this study. My mentor Dr. Daila S. Gridley deserves much
of my appreciation for her consistent support and her determined confidence to succeed
throughout the past years. She has also provided invaluable assistance in the preparation
and editing not only of this dissertation but of several manuscripts as well. I would also
thank the other members of my guidance committee, Dr. Istvan Fodor, Dr. E. Clifford
Herrmann, Dr. Penelope Duerksen-Hughes and Dr. Lawrence C. Sowers for their
intelligent instruction and commitment to my development. Also, both Dr. Michael
Pecaut and Dr. Tatyana Timiryasova deserve many thanks for their technical instruction
as well as their friendship in the areas that extended outside the laboratory. I am also very
grateful to the Department of Radiation Medicine of the Loma Linda University Medical
Center, and Dr. James S. Slater, chairman of the Department of Radiation Medicine, for
the use of facilities, and the Chan Shun International Foundation.
I would also express my appreciation to my fellows who have accompanied me
the most in the laboratory: Melba Andres, who has taught me so much and was a constant
resource in the performing of varied experiments; Dr. Lora Green, for her instruction in
the operation of the laser scanning cytometer; Radha Dutta-Roy and Judy Holbeck, for

iv

training and assistance in flow cytometry analyses; Dr. Xiaowen Mao, Dr. Greg Nelson,
Dr. Andre Obenaus, Dr. Glen Miller, Erben Bayeta, George Ashbury, Asma Rizvi,
Adeola Makinde, Farnaz Pirayesh and Lora Benzatyan for technical assistance.
Finally, I would express my love and appreciation for my family - Dad, Mom, my
big brother Licheng and my beloved husband Haitao. I owe them many thanks for giving
of themselves unconditionally supports. And I would also want to thank all my friends
for their priceless caring and assistance.

TABLE OF CONTENTS
Approval page.

in

Acknowledgements

iv

Table of Contents

vi

List of Figures

ix

List of Tables

xi

List of Abbreviations

xn

Abstract

xvi

CHAPTER ONE
I.

INTRODUCTION............................................
A. Cancer........................................................
1. Overview..............................................
2. Lung cancer.........................................
B. Radiation.....................................................
1. Overview..............................................
2. Energy deposition and cellular damage
3. Radiotherapy........................................
C. Tumor environment..................................
1. Overview..............................................
2. Angiogenesis.......................................
3. Tumor bed phenomenon.....................
D. Radiotherapy and anti-angiogenic therapy
E. Gene therapy..............................................
F. Cancer and immune system......................
1. Immune surveillance...........................
2. T lymphocytes....................................
3. B lymphocytes....................................
4. NK cells ..............................................
E. Significance of the study...........................

1
1
1
2
5

5
6
7

9
9
11
22
24

28
32
32
32
37
37

38

CHAPTER TWO
II.

METHODS AND MATERIALS...........................
A. In vitro experiments..........................................
1. pXLG-mEndo construction and expression
2. Cell lines and culture conditions................
3. Protein concentration and analysis.............
4. Western blot analysis..................................

vi

40
40
40

41
41
42

5. Mouse endostatin expression analysis.................................................
6. External beam irradiation....................................................................
7. 3H-thymidine incorporation method....................................................
8. Tube formation analysis......................................................................
B. In vivo experiments..................................................................................
1. Animals...............................................................................................
2. Tumor cells and tumor induction........................................................
3. Injection of plasmids..........................................................................
4. Localized y-irradiation........................................................................
5. Body mass, relative spleen weight values, lysed and unlysed spleen
preparation.........................................................................................
6. Peripheral blood collection and hematological analysis of blood and
spleen..................................................................................................
7. Cytokine analysis by ELISA...............................................................
8. Spontaneous blastogenesis of blood and spleen leukocytes...............
9. PHA-stimulated spleen supernatant....................................................
10. Mitogen-induced splenocyte proliferation..........................................
11. Flow cytometry analysis of spleen and blood cell populations..........
12. Cytokine analysis by bead array and flow cytometry.........................
13. Anti-CD31 immunohistochemistry.....................................................
C. Statistical analysis....................................................................................

42

43
43
44
45
45
45
47
47
47
48
49
50
51
51
52
54
54
56

CHAPTER THREE
III.

OBJECTIVE, HYPOTHESIS, AND AIMS OF THE RESEARCH
A. In vitro experiments....................................................................
B. In vivo experiments...................................................................

57
57
58

CHAPTER FOUR
IV.

RESULTS............................................................................................................ 60
B. In vitro experiments....................................................................................... 60
1. Specific Aim: Construct a plasmid vector expressing mouse endostatin
(PXLG-mEndo)....................................................................................... 60
2. Specific Aim2: Evaluate the functionality of pXLG-mEndo................. 64
B. In vivo experiments...................................................................................... 70
1. Overall sequence of experimental events................................................ 70
2. Specific Aiml: Analyze the kinetics of pXLG-mEndo expression in Lewis
lung tumor with time after plasmid injection......................................... 70
3. Specific Aim2: Determine optimal injection dose in combination with
radiation by quantifying the expression of pXLG-mEndo and levels of
pro-angiogenic factors in Lewis lung tumors........................................ 72
4. Specific Aim3Evaluate tumor progression and anti-angiogenesis effects
following single and multiple injections of pXLG-mEndo with and
76
without radiation

vii

5. Specific Aim4: Quantify effects of multiple combination treatments with
pXLG-mEndo and radiation on cytokines associated with angiogenesis
80
and leukocytes with anti-tumor activities
CHAPTER FIVE
V.

103
103
104
107

CONCLUSION....
A. Overview........
B. In vitro studies
C. Animal studies

CHAPTER SIX

VI.

112
DISCUSSION.................................................................
112
A. Gene therapy.............................................................
112
1. Overview.........................................................
113
2. Naked DNA gene transfer and cancer therapy
115
B. Radiation (y-ray and proton).....................................
C. Combined treatment in cancer therapy: radiotherapy, chemotherapy, and anti118
angiogenic therapy.............................................................................
120
D. Immune response: cancer immunotherapy........................................
E. Proposed rationale for combination treatment of pXLG-mEndo and
122
radiation

VII.

REFERENCES

123

vm

LIST OF FIGURES

PAGE

FIGURES

CHAPTER ONE
1.1. Tissue microenvironment............................................................................ 10
1.2. The balance hypothesis for the angiogenic switch..................................... 12
1.3. Direct and indirect angiogenesis................................................................. 18
1.4. Schematic structure of collagen XVIII........................................................ 19
1.5. Amino acid sequence of collagen XVIII domain NCI, which contains the
endostatin structure and identification of proteinase-sensitive sites......... 20
1.6. Endostatin receptors on endothelial cell surface......................................... 21
1.7. Schematic diagram of the hypothesized mechanisms of anti-angiogenic
effect of endostatin...................................................................................... 23
1.8. Schematic of changes in tumor vasculature during the course of antiangiogenic therapy...................................................................................... 27
CHAPTER FOUR
4.1. Construction of pXLG-mEndo using parental plasmid pWS4 and mouse
endostatin gene.......................................................................................... 61
4.2a Diagram of linear pXLG-mEndo............................................................... 62
4.2b The size of pXLG-mEndo shown by gel electrophoresis analysis........... 62
4.3. Expression of endostatin protein determined by western blot analysis..... 63
4.4. Time course study of expressed endostatin by irradiated and non-irradiated
65
Lewis lung carcinoma cells................................
67
4.5. In vitro endothelial cell tube formation analysis
4.6. Effect of pXLG-mEndo on the growth of human umbilical vein endothelial
68
cells with and without radiation
4.7. Effects of pXLG-mEndo on the growth of Lewis lung carcinoma cells with
and without radiation.................................................................................... 69
4.8. Sequence of experiment events in animal studies........................................ 71
4.9. Time course study of tumor endostatin and VEGF..................................... 73
4.10. Tumor endostatin and VEGF expression on the 7th day after combination
treatment....................................................................................................... 75
4.11. Antitumor effects of pXLG-mEndo and radiation...................................... 77
4.12. Antitumor effects of pXLG-mEndo and radiation...................................... 79
4.13. Antitumor effects of pXLG-mEndo and radiation...................................... 81
4.14. Antitumor effects of pXLG-mEndo and radiation...................................... 83
4.15. Visualization of the tumor vasculature using anti-CD31
immunohistochemi stry................................................................................. 86
4.16.Endostatin expression in tumor and plasma one day after the last
combination treatment.................................................................................. 89
4.17. VEGF expression in tumor and plasma one day after the last combination
90
treatment

ix

4.18.TGF-pl expression in tumor and plasma one day after the last combination
92
treatment..............................................................
99
4.19. Mouse Thl/Th2 cytokine CBA analysis: TNF-a
100
4.20. Mouse Thl/Th2 cytokine CBA analysis: IFN-y...
102
4.20.Mouse Thl/Th2 cytokine CBA analysis: IL-2....
CHAPTER FIVE
5.1. Rationale for anti-tumor effects of combination treatment of radiotherapy and
111
gene therapy
CHAPTER SIX
6.1. Physical characteristics of proton and photon beams

x

117

LIST OF TABLES

PAGE

TABLES
CHAPTER ONE

3
LI. Ten leading cancer types for cancer-related death in 2003
1.2. Cell markers used to distinguish between various lymphocyte and immune
14
cell subsets

CHAPTER FOUR
4.1. Inhibition effect of combing pXLG-mEndo and ionizing radiation on Lewis
lung carcinoma growth............................................................................... 85
4.2. Microvessel density in Lewis lung tumors................................................. 88
4.3. Effects of gamma irradiation and endostatin gene therapy on blood
characteristics one day after last combination treatment........................... 93
4.4. Effects of y-ray and endostatin gene therapy on lymphocytes, monocytes,
and granulocytes one day after last combination treatment....................... 95
4.5. Effects of y-ray irradiation and endostatin gene therapy on lymphocytes and
distribution of lymphocyte population one day post combination treatments.
97

xi

LIST OF ABBREVIATIONS
ACK

Ammonium chloride potassium

ADCC

Antibody-dependent cell-mediated cytotoxicity

ALCASE

Alliance for lung cancer advocacy, support and education

APC

Allophycocyanin

ATCC

American Type Culture Collection

B.D.F.

Beam divergence factor

CBA

Cytometric bead array

CBS

Calf bovine serum

CD

Cluster of differentiation

CMV

Cytomegalovirus

Co

Cobalt

ConA

Concanavalin A

cpm

Counts per minute

CTL

Cytotoxic T lymphocytes

DAB

diaminobenzidine

DMEM

Dulbecco’s minimum essential medium

dpm

Disintegrations per minute

EBM

Endothelial cell basal medium

ELISA

Enzyme-linked immunosorbent assay

FACS

Fluorescence activated cell sorter

FBS

Fetal bovine serum

FITC

Fluorescein isothiocyanate

Gy

Gray (1 Gy = 1 joule/kilogram of tissue)
xn

H&E

Hematoxylin and Eosin

HCT

Hematocrit

HESKA

Vet-Diff Hematology Analyzer

HGB

Hemoglobin

HUVEC

Human umbilical vein endothelial cell

IFN-y

Interferon-y

IL-2

Interleukin-2

IMDM

Iscove’s modified Dulbecco’s medium

i.p.

Intraperitoneal(ly)

LD50

Lethal dose for 50% of population

LET

Linear energy transfer

LLC

Lewis lung carcinoma

LPS

Lipopolysaccharide

LSC

Laser scanning cytometer

LTT

Lymphocyte transformation test

mAb

Monoclonal antibody

MCH

Mean corpuscular hemoglobin

MCHC

Mean corpuscular hemoglobin concentration

M-CSFMacropha

ge-colony stimulating factor

MHC

Major histocompatibility complex

MPV

Mean platelet volume

NK

Natural killer

NSCLC

Non-small cell lung cancer

xm

O.A.R.

Off axis ratio

OP

Output factor

PBS

Phosphate buffered saline

PDGF

Platelet-derived growth factor

pDNA

Plasmid DNA

PE

Phycoerythrin

PerCP

Peridinin chlorophyll protein

PHA

Phytohemagglutinin

PI

Propidium iodide

PLT

Platelet(s)

PMN

Polymorphonuclear

RBC

Red blood cell(s)

RBE

Relative biological effectiveness

RDW

Red blood cell distribution width

RPMI

Roswell Park Memorial Institute

RSW

Relative spleen weight

RT

Room temperature

s.c.

Subcutaneous(ly)

Sc

Collimator scatter factor

SCLC

Small cell lung cancer

SSC

Side scatter

TAP

Transporter associated with antigen processing

T.A.R.

Tissue to air ratio

xiv

TBE

Tumor bed effect

Tc

T cytotoxic lymphocytes

TCR

T cell receptor

TdR

Thymidine deoxyribonucleotide

T.F.

Tray factor

TGF-p

Transforming growth factor-(3

Th

T helper lymphocytes

TNF-a

Tumor necrosis factor-a

TSP

Thrombospondin-1

UV

Ultraviolet

VEGF

Vascular endothelial growth factor

WBC

White blood cell(s)

xv

ABSTRACT OF THE DISSERTATION
Ionizing Radiation and Endostatin GeneTherapy Against Lung Tumor
by
Xian Luo
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, June 2004
Dr. Daila S. Gridley, Chairperson
Although many advances have been made in radiotherapy, tumor radioresistance
and normal tissue damage continue to always be important issues for radiation
oncologists. Numerous reports have also documented that radiation exposure increases
the risk for malignancy and suppresses immune mechanisms. However, increasing
evidence has suggested that anti-angiogenic therapy that targets tumor blood supply may
alter abnormal tumor vasculature, thus synergizing radiotherapy. The governing
hypothesis of the present study was that modification of tumor vasculature by antiangiogenic gene therapy can increase the efficacy of radiotherapy and that radiation can
also improve DNA transfection efficiency by increasing expression of the administered
gene. The major goal of this study was to determine whether combination treatment of
endostatin gene therapy (pXLG-mEndo) and radiotherapy have a significantly greater
anti-tumor effect against lung carcinoma than either modality alone. The underlying
mechanisms were postulated to include alterations in the balance of cytokines critical for
generating tumor vasculature.
pXLG-mEndo, the unique plasmid containing a mouse endostatin gene under the
control of a cytomegalovirus (CMV) promoter was constructed in our laboratory. The
functionality of pXLG-mEndo was tested in vitro using both human umbilical vein
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endothelial cell (HUVEC) and Lewis lung carcinoma (LLC) cell lines with and without
radiation.
Combined anti-tumor efficacy of pXLG-mEndo and radiotherapy was tested in
the LLC model in C57BL/6 mouse. Different doses of plasmid were injected
intratumorally and 10 Gy of 60Co irradiation was applied locally to the tumor 16 hrs
thereafter. Multiple injections and irradiations were carried out in different animal
experiments. Tumor volumes and mouse weights were characterized; and
immunohistochemical analyses were performed on excised tumors to evaluate tumor
vasculature densities. In addition, angiogenic and anti-angiogenic factors were tested in
tumors and peripheral blood in order to identify changes associated with treatment. In
later studies, alterations in cytokine secretion and lymphocyte and other immune cell
distributions were also investigated after different combination treatments.
Collectively, the data demonstrated that the delivery of endostatin via pXLGmEndo as an adjuvant to radiation can significantly enhance the anti-tumor efficacy of
radiation therapy in the LLC mouse tumor model up to 50%. Furthermore, gene therapy
and radiotherapy had mutually beneficial effects. The findings also demonstrated for the
first time in this particular model that the changes of tumor angiogenic and antiangiogenic factors are correlated to tumor volumes and tumor vasculature densities.
Finally, changes in the relative status of immune cell compartments accompanied
ionizing radiation and gene therapy. These findings warrant further study and evaluation
of anti-angiogenic gene therapies in combination with radiation.
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CHAPTER ONE
INTRODUCTION
Cancer
Overview
Cancer is an abnormal growth of cells that rapidly reproduce despite restriction of
space, nutrients shared by other cells, or signals sent from the body to stop reproduction.
Cancer cells are often shaped differently from healthy cells, they do not function
properly, and they can metastasize or spread to many areas of the body. Tumors are
clusters of cells that undergo unregulated growth and division. Tumors can be benign
(noncancerous) or malignant (cancerous). Benign tumors tend to grow slowly and do not
spread, while malignant tumors can grow rapidly, invade and destroy nearby normal
tissues, and spread throughout the body.
In most cases, a single primary tumor arises in an organ. When the size reaches
approximately 1 -2 millimeters in diameter, the cells at the core of the tumor mass begin
to die due to insufficient nutrients from the environment. Because the more external cells
continue to divide while the more internal cells are dying, the tumor spheres can remain
at the same size and in the same place for months or years without readily detectable
change. However, tumor metastasis can occur and is typically more harmful and can be
fatal to the patients. Tumor metastasis is the process by which tumors spread from the
primary site (i.e., the original tumor site) to other tissues in the body. About 30% of
patients with newly diagnosed tumors already have detectable metastasis. Of the
remaining 70% who are clinically free of metastasis, about half of them will have
developed metastatic spread by the time of follow-up, even after potentially radical
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treatment of the primary tumor (Sugarbaker, 1981). Thus, at least 60% of cancer patients
have microscopic or clinically evident metastases at the time of primary tumor treatment.
Tumors of comparable size can sometimes have divergent behaviors, with respect
to metastatic potential, depending on their intrinsic aggressiveness and histologic type
(Tidier et al., 1982). It is also well known that tumors tend to be heterogeneous with
respect to the distribution of proliferative cells. For example, a subpopulation of highly
metastatic tumor cells pre-exists at a very early stage in the development of the primary
tumor (Fearon et al., 1990), and this metastatic subpopulation dominates the primary site.
Lung Cancer
Facts about lung cancer. Of all cancer related mortalities, lung cancer is the
leading cause of death in both men and women. In the United States, lung cancer is the
second most commonly diagnosed cancer and close to 28% of all cancer related deaths
were expected to be due to lung cancer in the year of 2003 (Table 1.1). The American
Cancer Society estimated that over 171,900 new cases and 157,200 deaths from lung
cancer occurred in the United States during 2003 (Jemal et al., 2003). Cancer ranks as the
second leading cause of death in the U.S.A., behind only heart disease, and accounts for
more than 1,500 deaths per day. This suggests a poor outcome following diagnosis and
treatment. Overall, the five-year survival rate for lung cancer stands at 15.8%, due
mostly to the fact that the majority of new cases are diagnosed at a regional or distant
stage in which survival is especially poor (Ries et al., 2000). Despite the current
technology for early detection, only 16% of new diagnoses are classified as localized
stage, and fewer than 25% of patients are asymptomatic at the time of diagnosis (Black,
1999).
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Ten leading cancer types for cancer-related deaths and new cases in
Table 1.1.
2003. Lung and bronchus cancer ranks first among the leading sites of estimated cancer
death. Adapted from Jemal et ai, 2003.

Estimated Cancer Deaths* - 10 Leading Sites by Gender, US, 2003
Women

Men
25%

31%
Lung & Bronchus
10%
Prostate
10%
Colon & Rectum
5%
Pancreas
Non-Hodgkin’s Lymphoma 4%
4%
Leukemia
4%
Esophagus
3%
Liver
Urinary Bladder
3%
3%
Kidney
22%
All other sites

15%

11%
6%
5%
4%
4%
3%
2%
2%
23%

Lung & Bronchus
Breast
Colon & Rectum
Pancreas
Ovary
Non-Hodgkin’s Lymphoma
Leukemia
Uterine Corpus
Brain
Multiple Myeloma
All other sites

Estimated New Cases* - 10 Leading Sites by Gender. US. 2003
Women

Men

32%
Breast
33%
Prostate
Lung & Bronchus
12%
14%
Lung & Bronchus
Colon & Rectum
11%
11%
Colon & Rectum
Uterine Corpus
6%
Urinary Bladder
6%
4%
Ovary
4%
Melanoma of the Skin
4%
Non-Hodgkin’s Lymphoma
Non-Hodgkin’s Lymphoma 4%
Melanoma of the Skin
3%
3%
Kidney
Thyroid
3%
Oral Cavity
3%
Pancreas
2%
3%
Leukemia
Urinary Bladder
2%
2%
Pancreas
All other sites
20%
All other sites
17%
*Excludes basal and squamous cell skin cancer and in situ carcinomas except urinary bladder.
Percentages may not total 100% due to rounding.
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Classification. Based upon histology there are two major types of lung cancer:
small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is much
more common. Of the estimated new cases of lung cancer each year, approximately 80%
are NSCLC (Ginsberg et al, 1997). The three major types of NSCLC are squamous
carcinoma, adenocarcinoma, and large cell carcinoma, all of which originate from
advanced cell types but bear a common classification. When localized, all have the
potential for cure with surgical resection. SCLC presents a more aggressive clinical
course, frequently involving distant metastases, and as a result localized treatments rarely
produce long-term survival (Prasad et al., 1989).
Current treatments. 85% of lung cancers are diagnosed in late stages (ALCASE,
1999) and are not amenable to surgery. Based upon a combination of clinical (physical
examination, radiologic imaging, etc.) and pathologic characteristics in lymph node
biopsy, bronchoscopy, and other specimens (Ginsberg, 1990), staging plays a critical role
in determination of appropriate therapy. In NSCLC, the most potentially curative
therapeutic option for pulmonary tumor is surgery. Radiation therapy has long been the
standard treatment for unresectable or inoperable NSCLC. However, 5-year survival with
limited stage NSCLC is only -10%, even after relatively high radiation doses of 60-65
Gy. In addition, up to 70% of patients fail local control (Dosoretz et al., 1993; Dosoretz
et al., 1992). Radiotherapy failure can be at least partly attributed to the fact that the
lungs are highly sensitive to radiation-induced injury. The concern for normal tissue
damage restricts the amount of therapeutic radiation that can be safely delivered, thereby
also limiting tumor curability (Emami et al., 1991; Geara et al., 1993). Attempts to
maximize the possibility for cure by increasing the dose of radiation can result in serious
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side effects (e.g., pneumonitis and fibrosis) that sometimes can be life-threatening (King
et al., 1996; McDonald et al., 1995). Chemotherapy is used for advanced-stage disease,
but typically offers only modest improvements in median survival and the overall
survival is poor (Souquet et al, 1993). The current and explorative chemotherapeutic
agents that show activity against NSCLC include taxol, taxotere, topotecan, vinorelbine,
and gemcitabine. Immunotherapies, including interferon and anti-idiotype regimens, are
also considered as possible treatment options for NSCLC. It should be noted that a
combination of modalities may be employed to reduce the likelihood of developing
regional or distant metastases. (Martini et al., 1995; Swisher et al., 2002).
Radiation
Overview
Life on earth has developed with an ever present background of radiation. Since
the discovery of X-rays by Wilhelm Conrad Roentgen more than a century ago, ionizing
radiation has increasingly influenced medicine as a treatment modality for a variety of
diseases, including cancer.
One way radiation exerts its effect on biological materials is through the transfer
of energy to electrons. Such absorption may lead to a state of either ionization or
excitation, depending on whether the radiation has sufficient energy to eject one or more
orbital electrons from either an atom or molecule or merely raise these electrons to a
higher energy level. Here we are concerned mainly with ionizing radiation from the
atomic nucleus. It occurs in two forms, photons and particles, at the high frequency end
of the energy spectrum. Ionizing radiation produces electrically-charged ions in the
materials it strikes. This process is called ionization. There are several types of ionizing
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radiation. X-rays and y-rays have no mass and consist of energy transmitted in discrete
bundles without the movement of material, just as heat and light are emitted from a fire
or the sun. They are virtually identical except that X-rays are generally produced
artificially and originate from outside the nucleus of an atom, whereas y-rays originate
within the nucleus or from the annihilation of charged particles. Unlike light, X-rays and
y-rays have great penetrating power and can pass through the human body. X-rays and yrays may be thought of as streams of photons, which deposit energy into tissues and cells.
These are in contrast to particulate forms of ionizing radiation (consisting of electrons,
protons, iron ions, etc.) which directly interact with atoms and molecules to produce
chemical and biological alterations (Bristow, 1998; Hall, 2000).
Energy deposition and cellular damage
X-rays and y-rays deposit energy into tissue by one of three processes: the
photoelectric effect, pair production, or the Compton effect. Of these, the Compton
effect is the most common in biological systems within the energy ranges used for
radiotherapy. In this process, the photon collides with an outer orbital electron, resulting
in a displacement of the electron and a redirection of the traveling photon. Both the
electron and photon are capable of causing further ionizations or excitations depending
on the initial energy of the photon (Bristow, 1998).
Cellular injury can occur either directly by the deposition of energy to the
macromolecules, or indirectly through the production of reactive radical intermediates
after the radiation interacts with cellular water. The mechanisms responsible for cellular
damage after ionizing radiation exposure include: (1) delay of cell division, (2)
reproductive failure, and (3) apoptosis. The injury type depends on the cell phenotype as
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well as the absorbed dose. Any of these types of cellular injury can happen as a result of
either direct or indirect cellular interactions with radiation (Bolus, 2001).
Although other cellular components and transduction pathways are also
influenced, genomic DNA has been traditionaly considered the primary target of
radiation. Damage to cellular DNA can occur by multiple processes including direct
ionization of DNA, reactions with electrons or solvated electrons, and reactions with
oxygen radicals (Ward, 1994). Double-strand breaks (dsb), comprise the majority of
biological damage and these correlate with the biological effectiveness of radiation.
However, due to the efficiency of repair mechanisms, including homologous and nonhomologous recombination for dsb, the role of single-strand and double-strand breaks in
critical damage has been redefined. Track structure analysis has revealed that clustered
DNA damage rather than simple double-strand breaks is likely to occur at biologically
relevant frequencies with ionizing radiation (Goodhead, 1994).
The production of reactive oxygen intermediates can also dramatically influence
DNA. When cells are irradiated, hydrolysis of water molecules due to energy deposition
can result in hydrogen atom and hydroxyl radicals. Thereafter, two hydroxyl radicals can
recombine to form hydrogen peroxide, which is highly unstable in the cell. Reactive
oxygen species, such as the hydroxyl radical, can also interact with proteins in the cell
membranes or the cytoplasm, some of which are likely to be involved in signal
transduction pathways (Bristow, 1998). This may result in the loss of an essential
enzyme, which could lead to cell death or a future mutation in the cell (Bolus, 2001).
Radiotherapy
Radiotherapy is the use of X-rays and other forms of ionizing radiation to treat
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disease. Many people with cancer will receive radiotherapy as part of their treatment.
Therapeutic beams can be delivered from outside the body, using X-rays or electrons, or
from within the body as exemplified by brachytherapy and radiolabelled monoclonal
antibodies. Radiotherapy works by destroying the cancer cells in the treated area.
Although some normal cells are invariably also damaged by the radiotherapy, they
usually can repair themselves more effectively compared to neoplastic cells.
It is estimated that approximately one-half of all cancer patients treated in the
U.S.A. will receive radiation as part of their therapeutic regimen (Coia, 1994). The
difficulty encountered in radiotherapy lies not in the ability to destroy the tumor but
rather in the necessity to limit total dose to the surrounding normal tissues. Complications
(both acute and late responses) due to normal tissue damage can be serious and
sometimes even life threatening. In the case of lung cancer, interstitial edema, exudation
of proteinaceous material into the alveoli, and desquamation of epithelial cells leading to
pneumonitis and pulmonary fibrosis are among the most common toxicities observed
following radiotherapy (McDondald et ai, 1995; Morgan et al., 1995; Peters, 1996).
Thus, the choice of total radiation dose and fractionation protocol must be based on
assessment of risk, which considers the severity of damage to normal tissue compared
with the probability of eradicating the tumor. We must also take into account different
factors which influence tumor responsiveness to radiation, including: hypoxia, proportion
of clonogenic cells, inherent radio sensitivity of the particular tumor type, and repair of
radiation damage (Hall, 1987; Travis, 1989). Furthermore, results from several tumor
models have shown a correlation between the level of apoptosis prior to irradiation and
the tumor response following radiation, thereby arguing that apoptosis may determine
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radiosensitivity (Meyn et al, 1993; Stephens et al., 1991). Treatment efficacy is also
affected by the extent of nutrient depletion, acidosis, and waste accumulation within
different regions of the tumor mass (Kim, 2001). Taken together, the efficacy of
radiation treatment is influenced by factors that are unique to each individual tumor, as
well as the inherent ability of the patient’s normal cells to tolerate radiation exposure.

Tumor Environment
Overview
Carcinogenesis is a process characterized by relentless multiplication of cells that
frequently results in destruction of the microenvironment. Malignant tissues are not
isolated and, as a consequence, normal cells associated with tumor can modulate its
progression and structural characteristics (Park et al, 2000). The converse is also true in
that tumors can alter the activities of normal cell populations. The three major steps in
tumor development are initiation, promotion, and progression. As tissue becomes
cancerous, there are reciprocal interactions between neoplastic cells, adjacent normal
cells sw i as stroma and endothelium, and their microenvironment. In fact, the formation
of a t._mor is dependent to some degree upon the surrounding cellular environment,
which at least partly helps to establish and support its growth. This surrounding
nonmalignant tissue, or tumor stroma, is a loosely defined structural framework that
surrounds and infiltrates the tumor. Tumor stroma is composed of fibroblasts, smooth
muscle cells, vasculature, and lymphatic channels as well as numerous cellular infiltrates
(Milas, 1998) (Figure 1.1). The composition and network of tumor stroma is unique to
each tumor type, because each tumor interacts differently with its surrounding
microenvironment.
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Figure 1.1. Tissue microenvironment. Both normal tissue and tumor
microenvironment rely upon an extensive interplay between a number of
different cells types and architecture including fibroblasts, migratory
immune cells, extracellular matrix and neural elements all supported by a
vascular network. Adapted form Park et al, 2000.
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Angiogenesis
Angiogenesis is the formation of new blood vessels by capillary sprouting from
pre-existing vessels, which is fundamental not only to tumor growth, but also for normal
physiological processes, such as growth, embryogenesis, fertility, and wound healing
(Campbell, 1997; Los and Voest, 2001; Tuxhom et al., 2001). Although most human
cancers may persist in situ for months in a prevascular phase, growing beyond 2-3 mm
requires new blood vessel formation (Folkman et al., 1989). Neovascularization prompts
tumor growth by increasing perfusion and supplying nutrients and oxygen. In addition to
these facilitating events, tumor cells are also stimulated in a paracrine fashion by several
growth factors produced by capillary endothelial cells (Folkman et al., 1996). The chance
of metastasis seems to increase with the size of the primary tumor, suggesting that
angiogenesis may play an important role in determining cancer spread. Indeed, the degree
of angiogenesis has proved to be predictive for metastatic disease in some neoplasms,
whereas areas with the highest density of microvessels contain cells that are most likely
to metastasize (Weidner et al, 1991). The small, quiescent tumor may remain clinically
undetectable for a long time in the so-called dormant state (Holmgren et al; Folkman,
1995). In transgenic mice carrying dominant oncogenes and/or knock-outs of tumor
suppressor genes, this phenomenon can be visualized. During early stages preceding the
appearance of solid tumors, the activation of angiogenesis is a discrete event in tumor
development, i.e., the angiogenic switch is turned on (Hanahan and Folkman, 1996;
Giordano and Johnson, 2001; Huss et al., 2001). Figure 1.2 shows the balance hypothesis
for the angiogenic switch. The normally quiescent vasculature can be activated to sprout
new capillaries (angiogenesis), a morphogenic process controlled by an angiogenic
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THE BALANCE HYPOTHESIS FOR THE ANGIOGNEIC SWITCH
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The balance hypothesis for the angiogenic switch. The
Figure 1.2.
normally quiescent vasculature can be activated to sprout new capillaries
(angiogenesis), a morphogenic process controlled by an angiogenic switch
mechanism. VEGF: vascular endothelial growth factor; bFGF: basic
fibroblast growth factor; TGF-pi: transforming growth factor-pi. Adapted
from Hanahan et al., 1996.
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switch mechanism. The prevailing evidence suggests that changes in the relative balance
of inducers and inhibitors of angiogenesis can activate the switch. In some tissues, the
absence of angiogenesis inducers may keep the switch off, while in others the
angiogenesis inducers are present but held in check by higher levels of angiogenesis
inhibitors. Thus, either reducing the inhibitor concentration (e.g., decreasing
thrombopondin-1 (TSP-1) by loss of a tumor suppressor gene) or increasing the activator
level (e.g., induction of VEGF by hypoxia) can each change the balance and activate the
switch, leading to the growth of new blood vessels. Angiogenesis is a complex multistep
process involving close orchestration of endothelial cells, extracellular matrix, and
soluble factors. This process can be divided in four stages: (1) proteolytic degradation of
the basement membrane and surrounding extracellular matrix, (2) endothelial cell
proliferation, (3) endothelial cell migration, and (4) tube formation and structural
reorganization (Hanahan and Folkman 1996; Jones and Fujiyama, 1999; Koop and Voset,
2002). The induction of this process is mediated by angiogenic factors released by both
tumor and host cells (Folkman, 1996; Blood et al., 1990) and depend on the net balance
of positive and negative regulators.
Pro-angiogenic factors. Angiogenic proteins may be expressed by tumor cells
themselves, or by host cells such as macrophages. A number of identified angiogenic
proteins are listed in Table 1.2. Among them, the most important are vascular endothelial
growth factor (VEGF), transforming growth factor-p (TGF-P), basic fibroblast growth
factor (bFGF) and hepatocyte growth factor (HGF).
VEGF is the key angiogenesis inducing factor. It is an endothelial cell specific
mitogen that induces endothelial cell proliferation and increases vascular permeability
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Table 1.2.

Regulators of angiogenesis. Adapted from Castells et al, 2002.

FVo-angiogenic factors
Angiogenin
Fibroblast growth fedors (acidic FGF; basic FGF FGF-2, FGF-4)
Granulocyte colony-stimulating factor
Hepatocyte growth factor (HGF)
lnterieukin-8
Placenta growth factor (PIGF)
Platelet-activating factor
Platelet-denved endothelial cell growth factor (PDEGF)
Platelet-derived growth factor (PDGF)
Ptoliferin
FVostaglandins E|( E3
Substance P
Transforming growth factor a (TGFa.)
Transforming growth factor (3 (TGF[3)
Tumor neo’osis factor a (TNFot)
Vascular endothelial grcrwth factors (VEGF A, VEGF B, VEGF C)
Anti-angjogenic factors
Angiostatin
Basic fibroblast growth factor (bFGF) soluble receptor
Cartilage-derived inhibitor (GDI)
Endostatin
Interferon ol, p, and y
Interleukin-1
InteHeukin-12
2- methoxyestradi ol
Platelet factor 4 (PF4)
FVolactin (16-kDa fragment)
R“otamine
Retinoic acid
Thrombospondin I
Tissue inhibitor of metalloproteinases (TIMP-I, TIM P-2,
TIM P-3)
Transforming growth factor (3 (TGFp)
Tumor necrosis factor ol (TNFa) (high concentrations)
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which is considered important for the initiation of angiogenesis (Campbell, 1997; Sener
et al., 1993). It is a major regulator of both physiological and pathological
neovascularization (Ferrara, 1997). VEGF plays a major role in regulating normal
embryonic vasculogenesis and angiogenesis. VEGF secretion is induced by hypoxiainducible factor 1 (HIF-1) production by tumor cells in response to a decrease in cellular
oxygen concentration (hypoxia) (Cvetkovic et al., 2001; Huss et al., 2001; Zhong et al..
1999, 2000). Originally isolated as the vascular permeability factor, VEGF was
subsequently shown to be a growth factor that induces endothelial cell proliferation. The
factor stimulates endothelial cells to degrade extracellular matrix, migrate and form tubes
in vitro. Endothelial cell survival in newly formed vessels is VEGF dependent. Consistent
with a role in cell survival, VEGF induces expression of anti-apoptotic proteins in
endothelial cells (Viekkola et al., 1999). Finally, VEGF overexpression has been
demonstrated in a number of human cancer cell lines, including those originating from
lung cancer (Koshikawa et al., 2003). Administration of monoclonal antibodies to VEGF
markedly reduced the number and size of lung and liver metastases in experimental
models (Wang et al., 1998; Blood et al., 1990). These latter findings emphasize the
importance of VEGF and the angiogenic process in metastatic spread of tumors.
TGF-p inhibits the growth of epithelial and hematopoietic cells, induces
apoptosis and plays an important role in tumor invasion and/or metastasis. TGF-(3 can
also promote extracellular matrix production, induce angiogenesis, and inhibit immune
function and therefore enhance tumorigenicity (Russell et al, 1998; Lee et al., 1999). The
factor is believed to play a dual role in carcinogenesis. Through its ability to inhibit
cellular proliferation, it suppresses tumor development in its early stages. However, in the
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course of tumor progression, malignant cells often acquire resistance to TGF-P, and
actually begin to secret large amounts of this cytokine. Furthermore, TGF-P facilitates
malignant progression in at least three ways. First, it supresses the activities of anti-tumor
eukocrytes infiltrating the tumor mass. Second, it acs to augment angiogenesis. Third, it
pomotes invasion and formation of metastases in a cell-autonomous manner that requires
TGF-P signaling activity, albeit at reduced levels, to be present in the tumor cells
themselves (Wieser, 2001).
The mechanisms of angiogenesis stimulation by TGF-p presumably combine
direct and indirect effects. TGF-P induces expression of the angiogenesis-inducing factor
VEGF (Pertovaara et al., 1994). Indirect stimulation of angiogenesis by TGF-p may also
occur through the potent chemoattractant activity of TGF-P for monocytes, which release
angiogenic cytokines (Sunderkotter et al, 1991). Also, TGF-p-induced expression of the
metalloproteases MMP-2 and MMP-9, and downregulation of the tissue inhibitor of
metalloproteases (TIMP) in tumor and endothelial cells can play a role. The end result is
to provide a protease-rich microenvironment conducive to the enhanced migratory and
invasive properties of angiogenically active endothelial cells (Hagedom et al, 2001). It
also directly induces capillary formation of endothelial cells cultured on a collagen matrix
(Madri et al, 1988). Thus, direct effects of TGF-P and indirect effects on the tumor
microenvironment stimulate tumor angiogenesis and promote tumor progression.
Anti-angiogenic factors. As mentioned above, angiogenesis is a complex and
highly regulated process. So far, more than 25 inhibitors have been identified (Table 1.2).
Among others, these factors include TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol],
metalloproteinase inhibitors, thalidomide, interleukin-12, angiostatin and endostatin
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(Folkman, 1996; Harris, 1997). Because of their potential roles in cancer treatment,
many of them are under investigation in phase I/II clinical trials. In recent years, it has
been demonstrated that systemic therapy with either angiostatin or endostatin causes
near-complete suppression of tumor-induced angiogenesis resulting in strong anti-tumor
activity (O’Reilly et al., 1997; Bergers et al., 1999).
There are two classes of angiogenesis inhibitors — direct” and “indirect”(Figure
1.3). Indirect angiogenesis inhibitors generally prevent the expression or block the
expression of their receptors on endothelial cells. Direct angiogenesis inhibitors, such as
endostatin, angiostatin, vitaxin and others, prevent vascular endothelial cells from
proliferating, migrating or avoiding cell death in response to a spectrum of proangiogenic proteins, including VEGF, bFGF, IL-8 and platelet derived growth factor
(PDGF). Direct angiogenesis inhibitors are less likely than chemotherapeutic drugs to
induce acquired resistance, because they target genetically stable endothelial cells rather
than unstable mutating tumor cells (Kerbe, 1991).
Endostatin is a 20 kDa fragment of the C-terminal domain NCI of collagen XVIII
(Figure 1.4 and Figure 1.5) that specifically inhibits endothelial cell proliferation,
migration and differentiation. It is a potent inhibitor of angiogenesis and tumor growth.
Endostatin can bind cell surface molecules such as heparan sulfate proteoglycan
(glypican-1 and 4), leading to signal transduction in endothelial cells via activation of
tyrosine kinase pathway. Researchers have identified glypican as a low-affinity receptor
for the endostatin molecule on the surface of endothelial cells. Glypican likely acts as a
coreceptor to a high-affinity receptor, that then signals intracellularly (Figure 1.6). The
high affinity of endostatin for heparin is due to a large number of basic residues, in
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Figure 1.3. Direct and indirect angiogenesis inhibitors. Direct
angiogenesis inhibitors target the microvascular endothelial cells that are
recruited to the tumor bed and prevent them from responding to various
endothelial mitogens and motogens. Indirect angiogenesis inhibitors target
proteins (e g. epidermal growth-factor tyrosine kinase) or their receptors,
on endothelium that are exprtessed by tumor cells. Adapted from Kerbel et
al, 2002
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COL-10). The endostatin fragment is a 20 kDa part of the NC-1 domain. Adopted
from Dixelius et al., 2003.
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Amino acid sequence of collagen XVIII domain NCI, which
Figure 1.5.
contains the endostatin structure, and identification of protease-sensitive sites.
The mouse sequence is shown in the top line and human substitutions underneath. A
dash indicates a deletion. Cysteines are consecutively numbered 1-4 on top. The Nterminal cleavage site of mouse endostatin is marked by an arrow. Arrowheads mark
endogenous cleavage sites in mouse NCI (^) and in human plasma forms (A)
including position 141/142. Thick lines underline sequences of mouse endostatin
where the entire structure was determined by Edman degradation and mass
spectrometry demonstrating the disulfide connections Cysl-Cys4 and Cys2-Cys3.
Thin lines show further sequences determined by Edman degradation of single-chain
peptides. Five sequence corrections of human NCI are marked by asterisks. Adapted
from Sasaki et al., 1998.
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Endostatin receptors on endothelial cell surface.
Figure 1.6.
Adapted from Jeff Cleary, News from Harvard Medical Dental &
Public Health Schools, May 4, 2001.
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particular arginines. Their distribution on the protein surface provides a likely binding
site for heparin (Hohenester et al., 1998).
Endostatin may have multiple direct effects that can inhibit endothelial cell
proliferation and migration. On the other hand, its indirect effects can control VEGF
production by endothelial cells or by tumor cells themselves (Figure 1.7) (Hajitou et al..
2002).

Regulation ofpro-angiogenic and anti-angiogenic factors. The specific
mechanisms that govern the expression of angiogenic growth factors in tumor cells are
still largely unknown, but dominantly acting oncogenes may have a great impact. In this
context, VEGF expression is induced by the mutant K-ras gene (Rak et al., 2000).
Besides this mechanism, ras genes also upregulate the expression of a variety of other
growth factors with direct or indirect stimulating effects on angiogenesis. Finally, this
regulatory function seems not to be exclusive for activating oncogenes, but rather tumor
suppressor genes may also be involved. For instance, the wild-type TP53 gene is known
to regulate genes that encode angiogenic inhibitors (Van Meir et al., 1994). Thus,
functional loss of TP53, which occurs in the majority of human tumors (Chene, 2001;
Horowitz, 1999; Roth et al., 2001) may tip the balance in favor of pro-angiogenic factors.
Tumor bed phenomenon
The tumor bed phenomenon was first noted more than 40 years ago (Barth et al.,
1961). It describes observations about delayed tumor progression following the
application of ionizing radiation to tumor stroma. When tumor cells are transplanted into
subcutaneous tissue that has previously been irradiated with high doses of radiation, the
establishment of tumor cells is delayed in comparison to growth in nonirradiated tissues
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(Hewitt and Blake, 1968; Urano and Suit, 1971). The possible underlying causes for this
effect are now thought to include a reduced ability of radiation-injured tissue to provide a
sufficient vascular supply to tumors (Jirtle et al, 1978; Penhaligon et al, 1988).
Consequently, the inhibition of angiogenesis is manifested in a relatively slow rate of
tumor progression.
Radiotherapy and Anti-angiogenic Therapy
Obliteration of the tumor vasculature is an effective means of achieving tumor
regression. Tumors induce angiogenesis, at least partly, through the secretion of VEGF.
However, it has been recently demonstrated that leukocytes (e.g., T lymphocytes,
neutrophils, and macrophages) are also capable of secreting the factor, suggesting that
they may also contribute to tumor vasculature formation. Biological response modifiers,
such as anti-angiogenic agents, pro-inflamatory and pro-thrombotic factors can induce
vascular obliteration, necrosis of tumors, and also may have direct cytotoxic effects when
used in combination with ionizing radiation (Hallahan et al, 1999). It appears now that
these agents, as a single form of therapy that block/prevent angiogenesis, would have to
be given long-term and would not produce cancer cure. However, the administration of
these factors, including endostatin, has been shown to enhance the anti-tumor effect when
used in combination with other modalities. Working as a single modality, radiation
damages endothelial cells by causing a progressive loss, and the loss rate is inversely
proportional to cell cycle time (Archambeau et al, 2000). The late effects of radiation
also include manifestation of injury, not only to the endothelial cell population, but also
to the basement membrane (Baker and Krochak, 1989). Furthermore, ionizing radiation
activates the inflammatory cascade and increases the pro-coagulative state within blood
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vessels of both tumors and normal tissues through induction of oxidative injury to the
endothelium (Hallahan et al., 1999).
At least some of the tumor cells that reside within the enlarging tumor volume are
always in a hypoxic microenvironment due to insufficient nutrients from the blood
supply. The signals triggered by hypoxia stimulate tumor cells to over-express proangiogenic factors. Anti-angiogenic therapy targets the tumor vasculature, derived from
local and circulating endothelial cells that are considered genetically stable. The fact that
a large number of tumor cells depends upon a small number of endothelial cells for their
growth and survival might also amplify the therapeutic effect (Folkman, 2001). Initially it
was also expected that these therapies would increase hypoxia in tumors, and thus limit
the effectiveness of radiation. Surprisingly, the combination of angiogenesis inhibitors
and radiotherapy has led to additive or synergistic response. This is counter-intuitive,
given that effective radiation therapy depends on ample blood flow to the tumor to
deliver oxygen. As a key investigtor of anti-angiogenic research, Dr. Jain first proposed a
rationale that could account for the increased benefit seen when radiation and an antiangiogenic factor are combined (Jain, 2001).

According to his hypothesis, anti-

angiogenic therapy ‘normalizes’ tumor vasculature before its destruction to improve the
delivery of oxygen that would, in turn, enhance the anti-tumor efficacy of radiation.
Unlike normal blood vessels, tumor vessels are structurally and functionally abnormal
(Figure 1.8a and b). An imbalance of pro- and anti-angiogenic factors causes endothelial
cell migration and proliferation. The excess endothelial cells and abnormal perivascular
cells contribute to the formation of torturous, dilated, and saccular blood vessels that are
poorly organized and hyperpermeable (Baish et al., 2000). These abnormalities, as well
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Schematic of changes in tumor vasculature during the course of
Figure 1.8.
anti-angiogenic therapy, a. Normal vasculature, composed of mature vessels and
maintained by perfect balance of pro- and anti-angiogenic molecules, b. Abnormal
tumor vasculature, composed largely of immature vessels, compromises the delivery
of therapeutics and nutrients, c. Direct or indirect anti-angiogenic therapies might
prune immature vessels, leading to more normalized tumor vasculature, d. Tumor
vasculature might be reduced to the point that it is inadequate to support tumor
growth and thus may lead to tumor dormancy.
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as the compression of blood vessels by cancer cells, can increase resistance to blood flow
and impair blood supply. If immature and inefficient blood vessels could be pruned by
eliminating excess endothelial cells, the resulting vasculature would be more ‘normal’
and hence more conductive to the delivery of nutrients (Figure 1.8c). This ‘normalized’
vasculature would still be more permeable and less ‘mature’ than its normal counterpart
(Figure 1.8a). Recent studies indicate that some anti-angiogenic therapies produce this
sort of normalization. For example, blocking VEGF or its receptor (VEGFR2) leads to
apoptosis of endothelial cells and a decrease in vessel diameter, density, and permeability
(Tsuzuki et al., 2000; Yuan et al, 1996; Kadambi et al., 2001), which decreases
interstitial fluid pressure and represent an improvement in global physiology and in the
metabolic microenvironment of tumors.
Gene Therapy
Gene therapy was originally conceived as a technique for correcting defective
genes responsible for disease development. Researchers may use one of several
approaches for correcting faulty genes: (1) a normal gene may be inserted into a
nonspecific location within the genome to replace a nonfunctional gene, the approach that
is most common; (2) an abnormal gene could be exchanged for a normal gene through
homologous recombination; (3) the abnormal gene could be repaired through selective
reverse mutation, which returns the gene to its normal function; and (4) the regulation of
a particular gene (i.e., the degree to which it is turned on or off) could be altered.
In studies of gene therapy for cancer, researchers are trying to improve the body's
natural ability to fight the disease or to make the cancer cells more sensitive to other more
conventional kinds of therapies. Many cancer gene therapy techniques under study are
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designed to: (1) replace missing or altered genes with healthy genes (e.g., p53); (2)
improve the patient’s immune response against cancer by stimulating the body’s natural
ability to attack cancer cells; (3) make cancer cells more sensitive to chemotherapy,
radiotherapy, or other treatments by transducing cancer cells with genes or by placing a
gene into the healthy blood-forming stem cells to make these cells more resistant to the
side effects of high doses of anti-cancer drugs; (4) destroy cancer cells by introducing
“suicide genes” into them; and (5) prevent cancer cells from developing new blood
vessels (angiogenesis). A review of gene therapy approaches for diseases of the lung,
with emphasis on cancer, has been recently published by Gill et al., 2004.
As stated previously, in many gene therapy studies, a "normal" gene is inserted
into the genome to replace an "abnormal," disease-causing gene. A carrier molecule
called a vector, must be used to deliver the therapeutic gene to the patient's target cells.
Currently, the most common vector is a virus (e.g., adenovirus and retrovirus) that has
been genetically altered to carry normal human DNA. Viruses normally encapsulate and
deliver their genes to human cells in a pathogenic manner, although latency also occurs.
Besides virus-mediated gene-delivery systems, there are several nonviral options for gene
delivery. The simplest and safest method is the direct introduction of therapeutic DNA
into target cells. Another nonviral approach involves the creation of an artificial lipid
sphere with an aqueous core. This liposome, which carries the therapeutic DNA, is
capable of passing the DNA through the target cell's membrane. Therapeutic DNA also
can be inserted into target cells by chemically linking it to a molecule that will bind to
special cell receptors. Once bound to these receptors, the therapeutic DNA constructs are
engulfed by the cell membrane and passed into the interior of the target cell. This
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delivery system tends to be less effective than other options. Although various nonviral
approaches have been developed, any method needs to be optimized in terms of the target
disease and transgene product. The most important information required is (1) efficiency,
(2) duration of transgene expression, (3) target cell-specificity of gene transfer, and (4)
the number of transfected cells following in vivo application of a vector. These
characteristics are determined by the properties of the vector used, as well as the route of
its administration, biodistribution, interaction with biological components, and the nature
of the target cells. Cell-specific gene transfer can be achieved by controlling the tissue
disposition of plasmid DNA (pDNA), although the interaction of the pDNA complex
with biological components might limit the specificity. The duration of transgene
expression is a complex function involving variables such as the cell type, transfection
method, and plasmid construct. The immune response often reduces the level and
duration of transgene expression. In addition, the number of transfected cells is
important, especially in cases in which the therapeutic protein localizes within the target
cells. Successful clinical application of nonviral gene delivery methods relies on the
development of such methods optimized for a particular disease.
Whether administered as recombinant protein (Dhanabal et al., 1999; Yamaguchi
et al., 1999), plasmid injection (Blezinger et al., 1999a; Blezinger et al., 1999b; Chen et
al., 1999), or gene transfection (Yoon et al., 1999), the anti-angiogenic factor endostatin
inhibits tumor growth with reduction of virtually all tumor neovascularization and
without detectable systemic toxicity in preclinical models. However, to be effective, antiangiogenic therapy with endostatin in tumor-bearing mice requires prolonged
administration and high doses of recombinant protein (Dhanabal et al., 1999b; O’Reilly
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et al., 1997). In addition, production of the functional polypeptide has proven difficult,
perhaps because of its physical properties and variations in the purification procedures
utilized by different laboratories (Dhanabal et al., 1999a; Taddei et al., 1999). Regimens
leading to persistence of endostatin have been shown to be more effective than the
intermittent peaks following bolus injections and to require a substantially lower dose in
order to achieve the same anti-tumor effect (Kisker et al., 2001). A few groups have
demonstrated that anti-angiogenic gene therapy with viral vectors may be a useful
approach for inhibiting tumor growth in pre-clinical models (Nguyen et al., 1998; Tanaka
et al., 1998). Although viral vectors have high transfection efficiency, safety issues and
potential toxicity limit their usages. In contrast, plasmid vectors for endostatin possess
low toxicity without compromising effective anti-tumor action (Blezinger et al., 1999a;
Blezinger et al., 1999b; Chen et al., 1999). The advantages and potential limitations in
the clinical application of angiogenesis inhibitors have been recently reviewed by Kerbel
et al. (Kerbel et al., 2002).
In our study, the advantages of using mouse endostatin gene therapy (pXLGmEndo) include: (1) relatively stable protein expression in the target tissue or circulation
for a longer period of time by intratumoral injection; (2) plasmid has low toxicity
compared to viral vector; (3) a larger amount of protein is generated when used together
with radiation since the mouse endostatin gene is under the control of a cytomegalovirus
(CMV) promoter; and (4) pure functional protein is obtained while avoiding the
complicated step of protein purification.
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Cancer and Immune System
Immune surveillance
Certain cells of immune system can secret pro- and anti-angiogenic factors and
they often infiltrate tumors. When it became known in the 1950s that tumor cells, despite
the fact that they are autologous, express transplantation rejection antigens, and that these
can evoke an immune reaction similar to that mounted against a foreign intruder, the
theory of immune surveillance was born. Although the concept of immune surveillance
has been debated for more than 50 years, there is considerable evidence supporting a role
for T lymphocytes, NK cells, monocyte-macrophages, and neutrophils in eradicating
malignant cells through apoptosis and/or cytolysis (Flescher et al, 1984; Hellstrom and
Hellstrom, 1998; Lichtenstein, 1986; Melder et al, 1993; Whiteside, 1995). In addition,
more immunogenic tumors, such as malignant melanoma, induce a stronger immune
response. The fact that this can lead to tumor rejection in transplant models suggests that
raising the level of the tumor-specific immune response alone might be sufficient to turn
the immune system into an effective weapon against the tumor. In addition, upregulating
immune defenses concurrently with tumor debulking by conventional techniques may
provide a means to eradicate micrometastases that later would become problematic.
Enhanced immune responsiveness may also provide more general protection, since
cancer patients are often immunosuppressed due to their disease and/or the therapies
employed.
T lymphocytes
The surface of each T lymphocyte displays thousands of identical T cell receptors
(TCRs) for a specific portion of an antigen. The TCR binds a biomolecular complex
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displayed at the surface of certain other cells called antigen-presenting cells (APCs). This
complex consists of a fragment of an antigen (i.e., a peptide) lying within the groove of a
major histocompatibility complex (MHC) molecule. Virtually all mature T cells also
express a cluster of differentiation (CD) molecule known as CDS. Most of these cells
belong to one of two subsets that are distinguished by the presence on their surface of one
or the other of two glycoproteins designated as CD4 and CDS. CD8+ T cells bind
epitopes that are presented in the context of MHC class I molecules. Almost all the cells
of the body express class I molecules. CD4+ T cells bind epitopes that are presented by
class II histocompatibility molecules. Only specialized APCs express class II molecules.
These include: dendritic cells, phagocytic cells like macrophages, and B cells.
T cytotoxic (CD8+) lymphocytes. Lymphocytes expressing both CD3 and CDS
are among the best characterized. These are known as cytotoxic T lymphocytes (Tc or
CTL) in that they can directly kill target cells after activation has occurred. TCR binding
in conjuction with other positive signaling induces the release of lytic mediators onto the
target cell or, in some cases, causes the target to undergo apoptosis (i.e., commit “cell
suicide” or programmed cell death). The Tc also multiplies, resulting in many cells with
the same antigenic specificity that can eliminate neoplastic, virus-infected, and otherwise
aberrant cells.
Experiments in mice and recent human clinical studies have clearly shown the
contribution of CD8+ Tc lymphocytes in the control of tumor development. CD8+ T
lymphocytes are a constitutive component of the immune response during the
development of cancer. In murine models, the efficiency of various cancer vaccines
mainly depends on their ability to induce CD8+ T lymphocytes. Administration of anti-
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tumor specific cytotoxic T clones in mice resulted in anti-tumor responses which directly
demontrated the therapeutic efficiency of these cells. However, infiltration of Tc cells
alone is not sufficient to elicit tumor regression, but appears to depend upon contribution
by CD4+ T cells and other mediators (Matsui et al., 1999). In addition, it has been
difficult to determine whether anti-tumor efficacy is related to the ability of Tc cells to
lyse tumor cells or to their ability to secrete certain cytokines at the tumor site (Kemp and
Ronchese, 2001). It is clear that Tc cells respond to MHC class I-associated tumor
antigens and initiate cell death. Killing of tumor targets by Tc cells can occur as a result
of participation of perforin, Fas ligand, or TNF-a. The latter two molecules induce
apoptosis in cells expressing the corresponding receptors. In addition, the release of
growth-suppressing factors, such TNF-a and IFN-y, is another means by which CD8+ T
cell-mediated tumor cell elimination can occur (Prevost-Blondel et al, 2000).
Unfortunately, in most cases during cancer progression, the presence of anti
tumor CD8+ T lymphocytes has not been associated with significant clinical responses.
Intrinsic functional abnormalities of these cells or a defect of CD8+ T cell migration to
the tumor may in part explain their failure to inhibit tumor development. On the other
hand, tumor cells also develop numerous immune escape mechanisms (down modulation
of tumor antigens, secretion of immunosuppressive factors, expression of anti-apoptotic
molecules by the tumor or pro-apoptotic factors inducing T cell death) that result in
resistance to or lack of CD8+ T cell attack (Ferrari et al., 2003; Scholl et al., 2003;
Swisher et al., 2002). In addition, tumor-associated antigens may be insufficient as
epitopes to elicit tumor rejection by CD8+ T cells, as in the case of MUT1 and MUT2 in
the Lewis Lung carcinoma model (Mandelboim et al, 1994). However, it has been
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demonstrated that co-stimulatory signals via CD28 and CD40 can override inhibitory
signals, causing lymphocyte proliferation as well as the production of TNF and IFN-y
(Hellstrom et al., 2001). It appears that IFN-y is the most critical cytokine with respect to
the anti-tumor effect mediated by Tc cells, whereas the production of type II cytokines by
the CD4+ T helper (Th) cells, including IL-4 and IL-5, seems to play a limited role
(Kemp and Ronchese, 2001; Matsui et al, 1999).
T helper (CD4+) lymphocytes. T helper cells (Th) play a central role in the
amplification and regulation of both cellular and humoral immune response. In contrast
to the CD8+ Tc lymphocytes, the CD4-expressing Th cells are able to recognize antigenic
peptides presented in the context of MHC class II molecules. These peptides may be
derived from either exogenous or endogenous sources. Antigenic proteins originating
from cells or cellular remains are taken up by specialized APC and the processed peptides
will be exposed in MHC class II at the cell surface, a process that is sometimes referred
to as cross-presentation. The interaction between APC (e.g., dendritic cells, DC) and
antigen-specific naive CD4+ Th cells will activate these cells to become functional. Both
the cross-talk between the Th cells and the APCs and the broad spectrum of Th cellderived cytokines contribute to the outcome of the cellular immune response.
Th cells have been classified into different subsets according to their cytokine
profile (Mosmann et al., 1996). Naive Th cells can produce IL-2, but very little or none
of any other cytokine. However, with repeated stimulation in the presence of IL-12, a
macrophage-derived cytokine, the naive Th cells differentiate into an intermediary subset
known as ThO that can then further differentiate into Thl and Th2 subsets. The so-called
Thl lymphocyte is characterized by the production of IFN-y and IL-2 amongst others,
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whereas Th2 cells produce IL-4, IL-5, IL-10, and others. These cytokines can crossregulate each other’s function and development (O’Garra, 1998). The cytokines have a
definitive influence on the outcome. Cytokines that are Thl cell-derived enhance cellular
immunity, whereas those that are Th2 cell-derived upregulate humoral immune
responses. IL-4 influences immunoglobin class switching to IgGl and IgE production by
B lymphocytes, whereas IFN-y promotes switching to IgG2a. Therefore these antibody
isotypes are correlated with the Th type of the immune response. Furthermore, the
cytokine IFN-y is well known for its potent upregulatory effects on antigen processing
and presentation. MHC class I and II as well as the expression of several other molecules
involved in these processes, like transporters of antigenic peptides (TAP-1 and TAP-2)
and proteasome components, are under the control of IFN-y (York et al., 1999).
Therefore, the Thl subset of the T helpers is correlated with an efficient cellular response
that includes Tc lymphocyte activities. The discrimination of Th cells into additional
types such as Th3 (Inobe et al., 1998; Chen et al., 1994) or so-called T regulatory cells 1
(Trl) type cells (Groux et a\., 1996; Groux et al., 1997) is characterized by production of
IL-10 and other inhibitory cytokines like TGF-(3.
An adequate Th response is essential in the initiation of immune reaction to
antigens. The inability to control tumor outgrowth can be due to inadequate activation of
tumor-specific Th cells leading to poor tumor-specific immunity. The main focus on anti
tumor CTL responses was based on the fact that most tumors are MHC class I positive
which often down-regulated or mutated, but lack MHC class II molecules (Melief et al..
2000). Moreover, CTL can directly kill tumor cells and their effectiveness in vivo has
been demonstrated many times (Melief et al., 1992).
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B lymphocytes
B cells participate in host defense by synthesizing antibody against infectious and
other immunogenic agents. Antibodies or immunoglobulins, which consist of five
different classes, bind unique epitopes on the surface of macromolecules. Engagement of
membrane-bound immunoglobulins on the surface of B lymphocytes leads to cell
division and differentiation into memory cells, lymphoblasts, and plasma cells (Cruse,
1999). Antibodies secreted from plasmacytes can neutralize the function of bound
macromolecules, activate complement upon crosslinking with antigen, generate cytolysis
of target cells through antibody-dependent cell-mediated cytotoxicity (ADCC), and
stimulate clearance by phagocytes.
B cells have a relatively low profile in anti-tumor immunity compared with other
lymphocytes. Their contribution to immune defense against neoplastic cell growth has
not been clearly established and appears to be quite variable. Mechanisms by which
antibodies may enhance tumor destruction include activation of complement at the tumor
cell surface, resulting in loss of osmotic integrity, and by mediating ADCC. In contrast,
the binding of IgG4, a subclass that does not activate complement or function in ADCC,
may protect tumor cells against immune attack.
Natural killer (NK) cells
Natural killer cells were discovered in the 1970's and are a subset of lymphocytes
involved in both innate immunity and tumor surveillance. These large granular
lymphocytes were first called “natural” killers because of their inherent ability to lyse
leukemia cells (Kiessling et al., 1975a; Kiessling et al, 1975b). Their granules, which
are relatively few in number compared to what is present in granulocytes, contain
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perforins that that can lyse target cells. NK cells are unique lymphocytes because they do
not require prior presentation of antigen in an MHC context before activation against
targets such as virally-infected cells and neoplastic cells. They have no immunological
memory and are independent of the adaptive immune system that is controlled by the T
lymphocytes. They do not possess the TCR/CD3 complex or the CD4 and CDS
molecules that are found on T cells. Although according to the classical understanding,
NK cells are not MHC restricted, they do possess a variety of receptors which are capable
of influencing cytolytic activity through signaling mechanisms. It has been shown that a
downregulation of MHC class I molecules incurs a susceptibility of transformed or
infected cells to NK cell lysis (Lanier et al, 1997; Raulet and Held, 1995). NK cell
expression of inhibitory receptors depends upon the MHC class I environment in which
the NK cell matures, although receptor expression is not permanently fixed during
maturation but rather is adapted to MHC class I changes on surrounding cells (Kase et
al, 1998; Khoo et al, 1998).
Besides their cytolytic capability, NK cells are able to amend the immune
response through the secretion of diverse cytokines including TNF and IFN-y (Carson et
al, 1999). The release and synthesis of IFN-y can strongly enhance the function of
macrophages against foreign cells, as well as mediate the differentiation of the Thl subset
(Tomura et al, 1999).
Significance of the Study
Cancer remains a formidable health problem worldwide and its prevalence is
expected to continue to increase. This is especially true for the United States and other
countries with an expanding population of elderly individuals. The long-term goal for
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this study is to determine whether endostatin gene expression can augment anti-tumoral
effects of radiation (y-ray and proton) against lung and other aggressive tumor types. The
research is unique because the plasmid pXLG-mEndo was constructed within our
laboratory and successfully tested for functionality against an aggressive tumor type. The
experimental design of the time-dose regimen was based upon our previous studies with
the parental plasmid vector, as well as new data generated with pXLG-mEndo. We seek
to better understand the interactive mechanisms of combination treatment with radiation
and anti-angiogenic modalities, including vasculature modification. Because the study is
in a lung cancer model, the data provide an important assessment of potential factors that
could be augmented for the prevention of primary tumor growth and metastasis.
Furthermore, since immunodepression is a common feature noted in cancer patients, due
to the disease and/or the implemented therapies, we also investigated immune status after
both radiation and gene therapy challenge to determine if shifts occurred that might
potentiate therapeutic efficacy. Overall, the findings indicate that highly significant anti
tumor effects can be achieved with this combination approach and serve to support
further investigations in the application of anti-angiogenic gene therapy as an adjuvant to
conventional radiation treatments. With further investigations, unique opportunities to
develop even more effective cancer therapies may be revealed.
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CHAPTER TWO
MATERIALS AND METHODS
In vitro Experiments
pXLG-mEndo construction and production
pXLG-mEndo was made in our laboratory as a plasmid carrying the mouse
endostatin gene. The sequence encoding the carboxyl terminal portion of the mouse
collagen XVIII was amplified by polymerase chain reaction (PCR) by use of Taq DNA
polymerase and the endostatin pBLAST vector (InvivoGen Inc., San Diego, CA) as a
template. PCR was carried out for 35 cycles by using 94°C for denaturation, 54°C for
annealing, and 72°C for extension. The complete sequence of the sense primer was: 5’CGCCGCGGAT GTAC AGGAT GCAACT CCTG-3 ’, and the anti-sense primer was: 5’GCATCGATCTATTTGGAGAAAGAGGTC. The amplified DNA fragment (617 base
pairs) was ligated into the pCR2.1 vector with SacII&nd C/a/cutting sites on each end by
using the T-A Cloning Kit (Invitrogen Corp., Carlsbad, CA). The SacII and Clal
restriction sites in sense primer and anti-sense primer are underlined respectively. The
pCR2.1 vector was purified by use of a QIAquick spin miniprep kit (QIAGEN Inc.,
Valencia, CA), digested with SacIIand Clal, and ligated into the pWS4 expression
vector. The pWS4 plasmid was kindly provided by Dr. Istvan Fodor from the Center of
Molecular Biology and Gene Therapy, Loma Linda University. The polylinker region
was deleted to enhance gene expression. pXLG-mEndo, as well as the empty vector
pWS4, contains a CMV promoter, an adenovirus tripartite leader (Avtl) sequence, a poly
A sequence and an ampicillin resistance gene. The transformation was carried out in
competent E. coli TOP 10 strain (Invitrogen Corp., Carlsbad, CA). Positive clones were
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sequenced on both strands and were also confirmed by gel electrophoresis analysis. Large
amounts of pXLG-mEndo and pWS4 for later animal experiments were obtained from
Aldevron LLC (Fargo, ND). The purified plasmid had the following specifications: < 5
EU/mg endotoxin, < 2% residual protein, residual RNA is undetectable, DNA homology
is predominantly supercoiled (by densitometry), and the purification (A260: A280 ratio)
is 1.89 (should be 1.8-2.0).
Cell lines and culture conditions
The mouse LLC cell line, obtained from America Type Culture Collection
(ATCC, Rockville, MD), was cultured in Dulbecco’s modified minimum essential
medium (DMEM) (Gibco™, Invitrogen Corp., Carlsbad, CA) supplemented with 10%
calf bovine serum (CBS) (HyClone Lab., Logan, UT), penicillin at 100 units/ml and
streptomycin at 100 pg/ml (Cellgro® by Mediatech Inc., Herndon, VA).
HUVEC cells were obtained from Clonetics Corp. (San Diego, CA) and were
grown in endothelial cell basal medium (EBM-2) (Clonetics Corp., San Diego, CA)
supplemented with 5% of fetal bovine serum (FBS). The cells were incubated at 37°C in
5% CO2 until near-confluency, harvested with lx trypsin solution, washed, and passed.
Protein concentration and analysis
The supernatants from cell cultures were concentrated by CENTRICON®YM-10
(10,000 MW cut-off) centrifugal filter devices (Millipore Corp., Billerica, MA). The
protein samples were centrifuged at 5000 x g for 1 hr using Sorvall RC 28S Super Speed
Centrifuge (GMI Inc., Albertville, MI). The concentration of protein was tested by the
Bradford method using a Beckman DU-600 machine (Thermo Galactic, Salem, NH).
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Western blot analysis
LLC cells were plated in six-well flat-bottom plates at IxlO6 cells/well, and
transfected using 4 pg of plasmid and 10 pi of Lipofectamine™2000 (0.75 mg/ml)
(Invitrogen Corp.) in serum-free DMEM. CBS was added 4 hrs after the transfection to
make a final concentration of 2%. The supernatants from each well were collected and
concentrated after 24 hrs. 100 pg of each preparation was loaded per well on 12% of
Tris-glycine gel, separated by SDS-PAGE, and transferred to Immobilon™-P transfer
membrane from Millipore Corp. (Bedford, MA). Anti-rabbit IgG (Sigma Chemical Co.,
St. Louis, MO) was used at a 1: 10,000 dilution followed by rabbit anti-mouse endostatin
polyclonal IgG (Chemicon Inc., Temecula, CA) at a 1:100 dilution. Pre-stained SDSPAGE standards (Bio-Rad Laboratories, Hercules, CA) were used to determine relative
protein size. Detection was performed using the Supersignal Chemiluminescent Substrate
(SuperSignal®, Pierce Biotechnology Inc., Rockford, IE).
Mouse endostatin expression analysis by ELISA
The concentration of mouse endostatin protein from cell cultures was quantified
by mouse-endostatin specific enzyme-linked immunosorbent assay (ELISA) (CytElisa
from CYTIMMUNE Sciences, College Park, MD). Absorbance was determined at 490
run by a microplate reader (DYNEX Technologies Inc., Chantilly, VA). LLC cells were
plated in six-well plates at 0.8 x 106 cells/well, and transfected using 4 pg of plasmid and
10 pi of Lipofectamine™2000 (0.75 mg/ml) (Invitrogen Corp.) in serum-free DMEM.
CBS was added 4 hrs after the transfection to make the final concentration as 2%. The
cell medium from each well was collected at 16 hrs after transfection and every 24 hrs
thereafter until the seventh day after transfection.
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External beam irradiation
LLC cells and HUVEC were irradiated with gamma (y) rays (photons) using an
AECL Eldorado therapy unit (Atomic Energy of Canada Ltd., Commercial Products
Division, Ottawa, Canada) containing a 60Cobalt (60Co) source located in the Animal
Care Facility in the Loma Linda University Medical Center. The Eldorado unit was
calibrated using a Capintec Model Pro6-G cylindrical thimble ionization chamber,
traceable to the National Institute of Standards and Technology (NIST). Exposure time
and subsequent total doses were determined by the following equations: (1) Dose rate =
OP (Output factor; corrects for decreasing output of source as a function of half life) x
T.A.R. (Tissue to air ratio; corrects for radiation scattered off the air between target and
sample) x Sc (Collimator scatter factor; corrects for radiation scattered off depleted
uranium collimator jaws) x T.F. (Tray Factor; corrects for specialty collimators) x O.A.R.
(Off Axis Ratio; corrects for the attenuation of the beam based on divergence from the
center) x B.D.F. (Beam divergence factor; correction for source (1/r2) intensity based on
the isocenter of 80 cm) and (2) Exposure time = desired dose/dose rate. Cells were
irradiated with the same physical dose of 2 Gy y-rays; the dose rate was ~1.1 Gy/min.
The vertical beam was adjusted to project a 30 x 30 cm field size, 80 cm from the
radiation source; cells were irradiated in a 20 x 20 cm area within this field.
Evaluation of combined effects of mouse endostatin and radiation by H-thymidine
incorporation method
HUVEC and LLC cells, both at 6 x 104 /well, were dispensed into 96-well plates.
The pXLG-mEndo and pWS4 (320 ng/well) with Lipofectamine™ 2000 from Invitrogen
Corp. were transfected into different cultures of HUVEC and LLC cells. Irradiation (2 Gy
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60Co) was performed at 16 hrs after transfection. A 50 pi aliquot of 1:50 diluted 3Hthymidine (3H-TdR; specific activity = 46 Ci/pmol; ICN Radiochemicals, Costa Mesa,
CA) was added into each well (1 pCi/well). After 4 hrs incubation at 37°C in 5% C02,
cells were harvested by the Tomtec Harvester96® (Tomtec Inc., Hamden, CT) and the
counts per minute (cpm) were quantified in a Wallac 1450 MicroBeta Trilux counter
(PerkinElmer Life Sciences, Boston, MA). The percentage of inhibition in DNA
synthesis in treated cells was based on the cpm obtained for non-transfected/nonirradiated controls of each cell type.
Tube formation analysis
HUVEC were plated in six-well plates at 1x106 cells/well, and transfected using 4
pg of plasmid (pXLG-mEndo or pWS4) and 10 pi of Lipofectamine™2000 (0.75 mg/ml)
(Invitrogen Corp., Carlsbad, CA) in serum-free DMEM. FBS was added 4 hrs after the
transfection to make a final concentration of 2%. 2 ml supernatant from each well were
collected after 48 hrs and concentrated by CENTRICON®YM-10 centrifugal filter
devices (Millipore Corp., Billerica, MA) as described previously.
The HUVEC suspension (2 x 105 cells/50 pi) were seeded in each well of BD
BioCoat™ Angiogenesis Plates (BD Biosciences, Bedford, MA). A volume of 100 pi
concentrated cell supernatants from pXLG-mEndo transfected, pWS4-transfected, and
non-transfected HUVEC cultures was added to individual wells. The plates were
incubated for 18 hrs at 37°C in a 5% CO2 atmosphere. Calcein AM (Molecular Probes,
Eugene, OR) was added at 400 pg/well immediately after the incubation. Tube formation
was analyzed using an Olympus fluorescence microscope and Image-Pro® Software
(Media Cybernetics, Carlsbad, CA).
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In vivo Experiments
Animals
Female C57BL/6 mice were purchased from Charles River Breeding
Laboratories, Inc. (Hollister, CA) at the age of 8-9 weeks. Mice were acclimatized for
one to two weeks prior to testing. The animals were maintained in self-contained filtertop microisolator cages (maximum of 10 mice per cage) in the Animal Care Facility at
Loma Linda University that is controlled for temperature, humidity, and a 12:12 hrs
light:dark cycle. Standard rodent food (Purina Lab Chow) and water were provided ad
libitum. Body weight and tumor dimensions were measured every day after the tumor cell
implantation. Mice were observed at least three times weekly for signs of toxicity
(lethargy, bloating, and ruffling of fur) during and after each treatment. Mice were
euthanized humanely by rapid asphyxiation in 100% CO2 in compliance with the
American Veterinary Medical Panel on Euthanasia. All animal care is under the direction
of a licensed veterinarian, and all studies involving animals received prior approval from
the Institutional Animal Care and Use Committee of Loma Linda University.
Tumor cells and tumor induction
LLC cells were obtained from the American Type Culture Collection (ATCC,
Rockville, MD). The cells have a doubling time of ~21 hrs in vitro and are relatively
resistant to many cancer therapies. LLC cells were cultured in DMEM (Gibco™,
Invitrogen Corp., Carlsbad, CA) supplemented with 10% CBS (HyClone Lab., Logan,
UT), penicillin at 100 units/ml and streptomycin at 100 pg/ml (Cellgro® by Mediatech
Inc., Herndon, VA). The cells were incubated at 37° C in 5% CO2 until near-confluency,
harvested with lx trypsin solution, washed, and passaged, the same as in the in vitro
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experiments. The passages of LLC cells used in the animal studies were all initiated at
passage 9 and injected into the mice at passage 11 in order to maintain, as closely as
possible, similar tumor induction and responsiveness to treatment throughout this portion
of the study.
LLC cells were harvested, washed, and counted using the trypan blue exclusion
method. Mice were injected subcutaneously (s.c.) in the right hind flank with 1x10
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cells/mouse in a volume of 0.1 ml of sterile PBS. Tumors were allowed to become
established and to reach a volume of ~200 mm3 (10-14 days after tumor cell
implantation) before treatment initiation. Tumor dimensions were measured with vernier
calipers and volumes were calculated: tumor volume (mm3) = (H x W x L)/2, where H =
height, W = width, and L = length of the tumor.
The LLC cell line is hypotetraploid with a modal chromosome number of 72 (Dus
et al., 1985). Syngeneic to C57BL mice, LLC cells can metastasize to the lungs of these
mice following s.c. implantation, consequently allowing for the assessment of both
primary and metastatic tumor growth. However, the metastatic potential of the cell line
varies by clone according to the expression of a diverse array of cell markers. This
potential is dependent upon the expression of c-jun, c-fos, TPS3, and the TGF-pl gene
(Narumi et al, 1993; Perrotti et al, 1991; Rizzo et al, 1993; Yamit-Hezi et al, 1994).
The expression of cell surface markers are correlated with metastases from the site of the
primary tumor and tumor-specific effectors as well as negative regulatory T cells home,
infiltrate and coexist in the tumor site (Gelber et al, 1992).
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Injection of plasmids
Different doses of pXLG-mEndo and parental plasmid pWS4, diluted in sterile
PBS to 50, 100, 200, and 400 pg in a volume of 80 pi, were injected intratumorally using
0.5 cc LO-DOSE® U-100 insulin syringes from Becton Dickinson (Franklin Lakes, NJ).
The injections were applied in 2-3 different locations at each tumor site. An equivalent
volume (80 pi) of sterile PBS was used in the control groups.
Localized y-irradiation
In experiments performed to compare the effects of pXLG-mEndo, independent
of localized irradiation as well as together with radiation, mice were anesthetized by
intraperitoneal (i.p.) injection of a low-dose xylazine (5.2 mg/kg) and ketamine (80
mg/kg) combination. Anesthetic was given to all mice, regardless of treatment group, in
order to equalize any effects due to stress. The utilized irradiation field size was
maintained at 20 x 20 cm. The tumor-bearing leg was extended into the field and
immobilized using masking tape. The body mass outside of the radiation field was
protected by 3-inch Lipowitz metal alloy blocks and the tumors were covered with a
bolus (‘superflab’) of 0.5 cm thickness. Total doses in these experiments were 10 Gy
(single fraction) or 20 Gy (10 Gy x 2 fractions) of y-radiation. All irradiation was
performed using the same equipment described in the in vitro experiments.
Body mass, relative spleen weight, and lysed/unlysed spleen preparation
Mice were weighed and spleens were excised from euthanized mice and also
weighed. Relative spleen weight (RSW) values were calculated as follows: RSW =
[spleen weight (g) x 104] -r body weight (g). Each spleen was then placed in a labeled 12
x 75mm polystyrene tube in a total volume of 2 ml lymphocyte transformation test (LTT)
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medium directly after weight measurement. LTT medium consisted of RPMI 1640
(Irvine Scientific, Santa Ana, CA) supplemented with 10% heat inactivated FBS,
penicillin-streptomycin, hepes buffer (Cellgro®, Mediatech Inc., Herndon, VA), and pmercaptoethanol (Sigma Chemical Co., St. Louis, MO). Spleens were mashed using
autoclaved wood applicator sticks to yield a single cell suspension. Mashed spleens were
then filtered into petri dishes using 40 pm cell strainers (Becton Dickinson, Franklin
Lakes, NJ). The remaining contents of tubes were rinsed with 1 ml of LTT medium and
filtered into the same petri dish. Leukocytes in aliquots of unlysed spleen suspensions
(-250 pi) were counted using the HESKA™ Vet ABC-Diff Hematology Analyzer
(HESKA Corp., Fort Collins, CO). The remaining unlysed samples were centrifuged at
1,500 rpm (200 x g) for 5 min, and the supernatant was discarded. Cold ammonium
chloride potassium (ACK) lysing buffer (0.1 M KHCO3/O.I54 M NH4CL/O.OI mM
EDTA) was added at 2 ml and tubes were incubated at 4° C for 5 min to lyse the
erythrocytes. The remaining leukocytes were washed with LTT medium, centrifuged
twice and finally resuspended in 2 ml of LTT medium. The cells were then counted and
dilutions were made to give a final concentration of 2 x 106 cells/ml.
Peripheral blood collection and hematological analyses of blood and spleen
Whole blood was collected in EDTA-containing tuberculin syringes by cardiac
puncture immediately following euthanasia of mice. Samples of whole blood, unlysed
spleen, and lysed spleen (12 pi of each preparation) were evaluated using the HESKATM
Vet ABC-Diff Hematology Analyzer (Heska Corp.). Unlysed and lysed spleen samples
were subject to dilution. The measurements included white blood cell count (WBC;
106/ml), red blood cell count (RBC; 109/ml), hemoglobin concentration (HGB; g/dl),
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hematocrit levels (HCT; percent volume of whole blood composed of RBC; %), mean
corpuscular volume (MCV; average volume per RBC; fl), mean corpuscular hemoglobin
(MCH; amount of hemoglobin in an average RBC; pg), mean corpuscular hemoglobin
concentration (MCHC; the concentration of hemoglobin in the RBC component of the
blood; g/dl), red blood cell distribution width (ROW; %), mean platelet volume (MPV;
fl), platelet counts (PLT; 106/ml) and eosinophil counts (106/ml). A 3-part differential
count for leukocytes (lymphocytes, monocyte/macrophages and granulocytes) was also
determined. The underlying principle of the instrument is based on electrical impedence,
a process whereby individual cells are passed through microscopic apertures for counting
and sizing. Electrodes maintain an electrical current across the aperture opening. Cellfree reagent conducts the current easily, but when a cell passes through the opening, it
acts as an insulator, causes resistance to the flow of current, and produces a spike in
voltage that is interpreted by the analyzer as a cell. The size of the voltage spike is
proportional to the size of the cell passing through the aperture, as defined by Ohm’s law
(U = R x I, where U = voltage, R = resistance and I = current).
Cytokine analysis by ELISA
Commercial ELISA kits were used to quantify the levels of mouse endostatin,
VEGF, and TGF-pi in plasma and tumor supernatants. Plasma was obtained from whole
blood samples after microcentrifugation at 8,000 rpm (4,000 x g) for 5 min. Tumor
supernatants were obtained from minced tissue centrifuged at 400 x g for 10 min. The
concentration of mouse endostatin, VEGF and TGF-pl from plasma and tumor
supernatant was quantified by mouse-endostatin specific ELISA assay (CytElisa from
CYTIMMUNE Sciences, College park, MD) and mouse-VEGF, mouse TGF-pi specific
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ELISA assay (Quantikine™ from R&D System Inc., Minneapolis, MN). Analyses were
performed following the assay protocol prescribed in the kit instructions. Briefly,
reagents and samples were brought to room temperature before use. Reagents, standards,
and controls were prepared according to the protocol. Typically, 50 jal of assay diluent
was added to the center of each well of the provided 96-well plate. Then 50-100 pi of
standard, control, or sample was added to the center of each well. The plate was tapped
gently for 1 min and allowed to incubate for 2-3 hrs at room temperature. Fluid from
each well was removed gently and wells were washed five times using wash buffer.
Antibody (50-100 pi) conjugate was added to each well after the washing procedure. The
plate was covered and allowed to incubate for 1-2 hrs at room temperature. The washing
procedure was repeated again and then 100-200 pi of substrate solution (color reagent
solution) was added to each well and the plate was allowed to incubate for 30 min while
protected from light. Finally, 50-100 pi of stop solution was added into each well. The
optical density of the wells was read at 450 nm or 490 nm using an ELISA plate reader
(Thermo Lab Systems, Chantilly, VA). The ELISA for TGF-pl included acidification
and neutralization steps, resulting in measurement of total TGF-pi (both active and latent
forms).
Spontaneous blastogenesis of blood and spleen leukocytes
The sequence of plate design for the 96-well plates was recorded to trace the order
of different samples for later analysis. Aliquots (50 pi) of whole blood and spleen
leukocyte suspensions were mixed with 150 pi of LTT medium. [ H]-TdR was added at
1 pCi/50pl/well. The samples were dispensed in triplicate into flat-bottomed wells of 96well microculture plates and incubated for 3 hrs at 37° C in a humidified atmosphere
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containing 5% CO2. After incubation, cells were harvested onto filters using a Tomtec
multiple sample harvester and the amount of [3H]-TdR incorporated into cell DNA was
counted by the Wallac beta scintillation counter. The WBC counts/ml obtained from the
automated Hematology Analyzer and volume (50 pi) of tested blood and spleen were
used to convert the raw cpm into cpm/106 leukocytes. Spontaneous blastogenesis was
standardized by the following formula: cpm/106 cells = (averaged cpm for triplicate wells
x 20)/(WBC count x dilution factor [if any]).
Mitogen-induced splenocyte proliferation
The sequence of plate design for the 96-well plates was recorded to trace the order
of different samples. Aliquots (100 pi) of each cell suspension (2 x 106 cells/ml) were
dispensed in triplicate into flat-bottom wells of 96-well microtiter plates and cultured
with 100 pi of phytohemagglutinin (PHA, Sigma Chemical Co., St Louis, MO), or
medium alone. The mitogen was pre-titrated for maximal response. The plates were
incubated at 37° C in 5% CO2 for two days. During the last 4 hrs of incubation, [3H]TdR was added at lpCi/50pl/well. The cells were harvested using a Tomtec multiple
sample harvester, and the uptake of radioactivity (cpm) was quantified by the Wallac beta
scintillation counter. Counts were standardized to be expressed as a stimulation index
(SI) as follows: SI = (cpm with mitogen - cpm without mitogen) 4- cpm without mitogen.
PHA-stimulated spleen supernatant
The sequence of plate design for the 96-well plates was recorded to trace the order
of different samples. The first six wells of each row were filled with 100 pi of pre-titrated
PHA (Sigma) diluted in LTT medium and the proceeding three wells were aliquoted with
100 pi of LTT medium alone. Aliquots (100 pi) of spleen leukocyte suspensions (2 x 106
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cells/ml) were dispensed into each row such that each sample was designated to a certain
row. The plates were then incubated at 37° C in 5% CO2 for two days. After two days,
stimulated and unstimulated cell supernatants were collected, aliquoted and stored frozen
for later analysis of cytokines.
Flow cytometry analysis of spleen and blood populations
Blood and spleen lymphocytes were directly stained with fluorescence-labeled
monoclonal antibodies (mAh) and measured by a FACSCalibur™ 4-channel dual laser
flow cytometer (Becton Dickinson, Inc., San Jose, CA). All mAbs, conjugated with
fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), allophyocyanin (APC), or
peridinin chlorophyll protein (PerCP), were purchased from Pharmingen (San Diego,
CA). Subpopulations of lymphocytes were defined by multiparameter flow cytometry
using side scatter (SSC-cell granularity) versus CD45 (leukocyte common antigen) and
appropriate antibodies labeled with unique fluorochromes. The use of multiple antibodies
enabled single-antibody histogram analysis as well as resolution of distinct cell
populations.
For this study, the mouse “Lyse/No Wash Staining Protocol” developed by
Pharmingen was used to assess lymphocyte populations within blood and spleen samples
(4-color, 2-tube preparation). Originally, Pharmingen in collaboration with Becton
Dickinson produced these custom mAb mixtures according to our specifications. The
mAb are specific for CD3+ T, CD3+/CD4+ Th, CD3+/CD8+ Tc, B220+ B, and NK1.1+
NK cells and are available for use by investigators in the Radiobiology Program at Loma
Linda University, as well as others. More specifically, the custom antibody conjugates
consist of the following:
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CDS * FIT C/CD 8 * PE/CD45 * PerCP/CD4 * APC
Clones 145-2C11, 53-6.7, 30-F11, and RM4-5 respectively.
and
CD3*FITC/NKl.l*PE/CD45*PerCP/B220*APC
Clones 145-2C11, PK136, 30-F11, and RA3-6B2 respectively.

Twenty microliters of custom antibody combinations were aliquoted into 12 x 75 mm
polystyrene tubes. Peripheral blood and spleen samples were then aliquoted (50 pi) into
designated tubes and incubated for 20 min in the dark at room temperature after mixing.
An aliquot (450 pi) of pre-warmed lysing buffer was added to each tube. Tubes were
then capped, vortexed, and incubated in a 37° C water bath for 20 min. Following
incubation, samples were placed on ice until flow cytometry data acquisition.
“Cell gating” was used to specifically capture the cells of interest and then display
other parameters within the gated lymphocyte population. In this study, leukocytes were
resolved using CD45 to initially gate the lymphocytes prior to assessing
immunophenotype by other antibodies. Approximately 10,000 lymphocyte events/tube
were acquired with the threshold trigger on FL3 using the Lyse/No Wash FACSComp
setting. Acquisition occurred within 6 hrs of staining.
Multiparameter analysis was performed using CellQuest™ software version 4.0
(Becton Dickinson). Purity calculations of the gated lymphocytes, which were based on
the sum of the percentages of B220, CD4, CDS, and NK1.1 positive cells, were used to
convert the raw percentage of each subpopulation to normalized percentages. To obtain
the absolute density of each lymphocyte population, the following formula was used:
number of cells in population/ml = number of leukocytes/ml x percentage of population.

53

Cytokine analysis by bead array and flow cytometry
The levels of IFN-y, TNF-a, IL-2, IL-4, and IL-5 were quantified in 50 ql
samples of supernatants obtained from PHA-stimulated splenocytes (see above for
procedure) using the Cytometric Bead Array Assay (CBA Assay, Becton Dickinson)
according to the manufacturer's instructions. These cytokines are typically secreted by
activated Thl (IL-2 and IFN-y) and Th2 (IL-4 and IL-5) lymphocyte subsets.
Supernatants from non-stimulated cells were collected and tested for background
cytokine levels. This assay uses amplified fluorescence detection by flow cytometry to
measure soluble analytes in a particle-based immunoassay. The CBA capture bead
mixture is in suspension to allow for the detection of multiple analyses in a small volume
sample. Cytokine concentrations in each test sample were interpolated from the
appropriate standard curve.
Anti-CD31 immunohistochemistry
Tumor samples were stained by anti-CD31 antibody and tumor vessels were
detected by anti-rat immunoglobulin horse radish peroxidase (HRP) detection kit (BD
Biosciences Pharmingen, San Diego, CA). Briefly, tumors were excised from six mice in
each treatment group and were fixed in Zinc Fixative by placing freshly dissected tumor
pieces (no lager than 3 mm in thickness) in Zinc Fixative and incubating for 24-48 hrs at
RT. Tissues were then processed according to the schedule shown below:
45
45
45
45
45
45
45
45

min
min
min
min
min
min
min
min

Station #1
Station #2
Station #3
Station #4
Station #5
Station #6
Station #7
Station #8

Zinc fixative
50% Alcohol
70% Alcohol
95% Alcohol
100% Alcohol
100% Alcohol
100% Alcohol
Histo-Clear
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45 min
45 min
1 hour
1 hour

Histo-Clear
Histo-Clear
Histo-Clear
Histo-Clear

Station #9
Station #10
Station # 11
Station # 12

Immunohistochemistry was then performed as described in the next steps:
1. Section paraffin blocks at the desired thickness (4-5 pm) on a microtome and float on
a water bath containing deionized or distilled water.
2. Transfer the sections onto a Superfrost Plus slide. Allow the slides to dry overnight

and store slides at RT until ready for use.
3. Place the slides in a 55°C oven for ten minutes to melt the paraffin. Deparaffinize

slides in 2 changes of histo-clear solution for 5 min each.
4. Transfer slides to 100% alcohol, 2 changes for 3 min each and transfer once through

95% alcohol for 3 min.
5. Block endogenous peroxidase activity by incubating sections in 3% H2O2 solution in
methanol for 10 min. Rinse in PBS twice for 5 min each time.
6. Apply enough 1:20 diluted primary antibody and isotype control antibody to cover
tumor section and incubate at 4°C overnight in a humid chamber.
7. Rinse slides in 3 changes of PBS, 2 min each. Apply 1:50 diluted biotinylated

secondary antibody and incubate at RT for 30 min.
8. Rinse slides in 3 changes of PBS, 2 min each. Apply Strepavidin/HRP to each slide
and incubate at RT for 30 min.
9. Rinse slides in 3 changes of PBS, 2 min each.
10. Prepare diaminobenzidine (DAB) according to manufacturer’s specifications.
11. Add DAB solution to each slide, making sure all the section is covered by solution.
Allow incubate 5 min or less.
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12. Rinse slides well in water 3 times.
13. Counterstain slides:
a. Dip twice in Hematoxylin.
b. Rinse thoroughly in water.
c. Dip twice in dilute ammonia water.
d. Rinse thoroughly in water.
14. Dehydrate through 4 changes of alcohol (70%, 95%, 100% and 100%) for 5 min.
Clear in 3 changes of histo-clear and coverslip.
Five sections per mouse and a total of five high-power fields (400 x) per section
were examined by use of an Olympus microscope equipped with a Roper Scientific
digital camera. Vessel counts were determined by use of Image-Pro® imaging software
(MediaCybernetics, Carlsbad, CA).
Statistical analysis
The data were subjected to one-way and/or two-way analysis of variance
(ANOVA) and Tukey’s HSD (honestly significant difference) multiple range test using
SigmaStat1M software version 2.03 (SPSS Inc., Chicago, IL). A p value of < 0.05
indicated statistical significance.
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CHAPTER THREE
OBJECTIVE, HYPOTHESIS, AND AIMS OF RESEARCH
The long-term goal of this research is to develop new therapeutic approaches that
have potential to improve the management of highly aggressive cancers. More
specifically, our studies focus on development of agents that either sensitize tumors to
radiation damage or that selectively protect normal tissues during radiotherapy. The study
evaluated a new plasmid vector for endostatin that was constructed in our laboratory
(pXLG-mEndo) in concert with radiation (60Co y-rays) in an immunocompetent animal
model of lung tumor. The overall hypothesis was that the combination of pXLG-mEndo
and radiation will have a significantly greater anti-tumor effect against lung carcinoma
compared to either modality alone and the mechanisms of action will include
modification of tumor vasculature. In addressing this hypothesis, several specific aims
were set forth:
In vitro Specific Aims:
Specific aim 1: Construct a plasmid vector expressing mouse endostatin (pXLGmEndo)
Plasmid pXLG-mEndo was constructed in our laboratory in order to introduce
therapeutic endostatin DNA. pXLG-mEndo carries the mouse endostatin gene which is
under the control of a CMV promoter.
Specific aim 2: Evaluate the functionality of pXLG-mEndo
Based on the mechanism of endostatin action, the function of pXLG-mEndo was
tested using an in vitro assay for endothelial cell tube formation. The effects of the
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construct were also tested with and without radiation using both HUVEC and LLC cell
lines.
In vivo Specific Aims:
Specific aim 1: Analyze the kinetics of pXLG-mEndo expression in Lewis lung
tumors with time after plasmid injection
Preliminary studies showed that the expression of pXLG-mEndo in vitro is timedependent. The kinetics of pXLG-mEndo expression is very important in selecting the
time points of multiple injections needed to maintain or enhance the anti-tumoral effects
of mouse endostatin.
Specific aim 2: Determine the optimal injection dose in combination with radiation
by quantifying the expression of pXLG-mEndo and levels of pro-angiogenic factors
in Lewis lung tumors
The expression of pXLG-mEndo is based not only on the initial injection dose but
also on many other factors, such as the maximum amount of transfected DNA the tumor
cells can express and the complex interactions with the pro-angiogenic factors, e.g.,
VEGF and TGF-pi. The optimal dose of pXLG-mEndo needs to be identified before
further analysis of the effects of mouse endostatin.
Specific aim 3: Evaluate tumor progression and anti-angiogenesis effects following
single and multiple injections of pXLG-mEndo with and without radiation
Based on the results of in vivo Specific Aims 1 and 2, these studies focused on the
evaluation of the effects of mouse endostatin and radiation between single and multiple
treatments.
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Specific aim 4: Quantify effects of multiple combination treatments with pXLGmEndo and radiation on cytokines associated with angiogenesis and leukocytes with
anti-tumor activities
Complete animal experiments were set up after identifying the optimal dose and
evaluating the kinetics of pXLG-mEndo expression and the effects of the single and
multiple treatments with each modality. A number of critical parameters, such as tumor
volume, tumor vessel density, levels of pro-angiogenic and anti-angiogenic factors, and
leukocyte populations were quantified to evaluate the anti-tumor efficacy and safety of
combination treatment with pXLG-mEndo and radiation.
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CHAPTER FOUR
RESULTS
In vitro Experiments
Specific aim 1: Construct a plasmid vector expressing mouse endostatin (pXLGmEndo)
Development of the pXLG-mEndo construct carrying the mouse version of the
endostatin gene. Plasmid pXLG-mEndo was successfully constructed in our laboratory as
described in the Materials and Methods section (Chapter Two). A schematic
representation of pBLAST mEndostatin v.13 (source of endostatin gene), pWS4 (plasmid
into which the gene was inserted), and pXLG-mEndo (final plasmid construct) is shown
in Figure 4.1. The nucleotide sequence of both strands in positive clones was determined
by DNA sequencing and the size (kb) of pXLG-mEndo was also confirmed by gel
electrophoresis analysis (Figure 4.2). The size of pXLG-mEndo is 4614 bp and it is under
the control of a CMV promoter.
Detection of endostatin protein expressed in LLC cells using western blot
analysis. To test the expressed mouse endostatin, pXLG-mEndo was transfected into
LLC cells, and the cell culture supernatants were subjected to western blot analysis.
Comparison of the resulting band with those of concurrently separated proteins of known
molecular weight showed that the protein derived from pXLG-mEndo was 20 kDa, a
correct match for endostatin (Figure 4.3).
Identification of expression level of mouse endostatin in LLC cells. A 7-day time
course study of expressed endostatin was done in order to quantify the level of mouse
endostatin protein secreted by LLC cells both with and without radiation. pXLG-mEndo
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Figure 4.1. Construction of pXLG-mEndo using parental plasmid pWS4 and
mouse endostatin gene. The final end product contains the cytomegalovirus (CMV)
promoter and the adenovirus tripartite leader (Avtl) sequence at the 5’ end that binds
translation initiating proteins with higher affinity than do cellular mRNAs. Thus, the
translation of the endostatin gene is greatly enhanced.
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Endostatin

CMV-pro

Avtl

secretion seq

SV40 ter

Figure 4.2a. Diagram oflinear pXLG-mEndo. CMV-pro: cytomegalovirus
promoter; Avtl: adenovirus tripartite leader; Secretion seq: secretion sequence;
SV40 ter: Simian Virus 40 replication terminus site.

pXLG-mEndo

5.0 kb
4.0 kb ->
3.0 kb

VwmNpiNii

mHUMP

(4.6 kb) shown by gel
Figure 4.2b. The size of pXLG-mEndo
electrophoresis analysis. Lane 1: 1 kb Ladder (BioRad Laboratories); Lanes
2-5: pXLG-mEndo digested by SacII.
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Marker
1
K Da

pWS4
2

3

pXLG-mEndo
4

5

m

110.0
51.2
36.2
29.0
19.0

Expression of endostatin protein determined by western blot
Figure 4.3.
analysis. Endostatin was expressed as a single band of 20 kDa protein (lanes 4
and 5). Transfection of the vector plasmid (pWS4) was used as a negative control
(lanes 2 and 3). Lane 1: SDS-PAGE marker (BioRad Laboratories).
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was transfected into LLC cells with the assistance of Lipofectamine2000™ transfection
kits as described in detail in the Materials and Methods (Chapter Two). Two Gy of yradiation was applied 16 hrs after the transfection. The cell medium from each well was
collected at 16 hrs, and every 24 hrs thereafter until the seventh day after radiation
exposure. For non-irradiated cells, the expression peak of endostatin protein (13.6 ng/ml)
was on day 3 after transfection. For irradiated cells, the expression peak (16.7 ng/ml) was
on day 2 after transfection. The peak level of endostatin produced by the irradiated cells
was significantly higher than that of their non-irradiated counterparts at days 2-5 post
irradiation (p< 0.001), except for the time points of 16 and 24 hrs post-irradiation
(possibly due to the recovery period of LLC cells after radiation exposure). The time
course of mouse endostatin expression by LLC cells is shown in Figure A A. In vitro
ELISA and immunocytochemical analysis for the therapeutic gene demonstrated that the
protein was not in the transfected LLC cell plasma, but in the conditioned medium. This
indicated that secretion of the endostatin derived from pXLG-mEndo was successfully
accomplished by the tumor cells.
Specific aim 2: Evaluate the functionality of pXLG-mEndo
Evaluation of inhibition effect of mouse endostatin gene on endothelial cell tube
formation. Tube formation is one of the important stages of angiogenesis after endothelial
cell proliferation and migration. Endothelial cells are capable of differentiating in vitro to
form capillary-like structures. BD Matrigel Matrix is an ECM (extracellular matrices)
preparation composed primarily of laminin, collagen IV, heparan sulfate proteoglycan,
and a number of growth factors. It is a high throughput assay to screen for angiogenesis
inhibitors. In our study, endothelial cells (HUVEC) were treated with equal amount of
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Figure 4.4. Time course study of expressed endostatin by irradiated and
non-irradiated LLC cells. LLC cells were transfected with pXLG-mEndo
and 2 Gy 60Co irradiation was applied 16 hrs after transfection. Cell
supernatants were collected immediately after radiation exposure and every 24
hrs thereafter until the seventh day after transfection, a. p< 0.001 versus nonirradiated cells at same time noint.
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pXLG-mEndo, pWS4 empty vector, or PBS to determine if the endostatin protein
derived from pXLG-mEndo was capable of inhibiting tube formation. The images of
tubular structures were obtained using an Olympus fluorescent microscope and ImagePro® imaging software. As shown in Figure 4.5, compared to the non-treated control and
pWS4 empty vector-treated HUVEC, tube formation was inhibited in the endothelial
cells treated with pXLG-mEndo. This observation strongly suggests that our pXLGmEndo is functional in inhibiting a critical step in angiogenesis.
Evaluation of combined effects of mouse endostatin gene and radiation. Based on
the mechanism that endostatin inhibits the growth of endothelial cells and therefore
inhibits angiogenesis and tumor growth, the functionality of pXLG-mEndo was tested in
concert with radiation. The pWS4 and pXLG-mEndo plasmids were transfected into
HUVEC and EEC cells. A dose of 2 Gy y-radiation (60Co) was delivered at the time
point of 16 hrs after transfection. Based on 3H-TdR incorporation, the pXLG-mEndo
alone resulted in highly significant depression in DNA synthesis by both HUVEC and
EEC cells compared to cells transfected with the pWS4 parental vector and control cells
with no plasmid (p< 0.005) (Figures 4.6 and 4.7). The percentages of inhibition obtained
for HUVEC cells treated with pXLG-mEndo were 36.72%, 43.14%, and 43.48% from
days 1 -3 after transfection and were substantially higher compared to cells treated with
the pWS4 empty vector (i.e., 18.25%, 11.63% and 16.03% at the same time points). For
EEC cells treated with pXLG-mEndo, the inhibition percentages were 31.48%, 51.67%,
and 60.00% compared to pWS4 treatment that resulted in values of 13.02%, 7.20%, and
6.91% respectively from days 1-3 after transfection. Most importantly, the combination
of pXLG-mEndo and radiation resulted in significantly greater inhibition of HUVEC and
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Figure 4.5. In vitro endothelial cell tube formation analysis. The effects
of pXLG-mEndo expression on human umbilical vein endothelial cells
(HUVEC) were evaluated by BD BioCoatTM Angiogenesis SystemEndothelial Cell Tube Formation assay.
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Figure 4.6. Effect of pXLG-mEndo on the growth of human umbilical
vein endothelial cells (HUVEC) with and without radiation (2 Gy ^Co).
The inhibition percentage is based on the amount of 3H-thymidine
incorporated into DNA by nontransfected HUVEC. * p< 0.001 compared to
pWS4 +/- 2 Gy at each respective time point.
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Figure 4.7. Effects of pXLG-mEndo on the growth of Lewis lung
carcinoma (LLC) cells with and without radiation (2 Gy of ^Co irradiation).
The inhibition percentage is based on the amount of 3H-thymidine incorporated
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at each respective time point.
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LLC cell growth over a 3-day period post-irradiation (p<0.05 or less compared to either
modality alone) (Figures 4.6 and 4.7).
In vivo Experiments:
Sequence of experiment events
The overall sequence of events performed in the animal experiments is shown in
Figure 4.8. LLC cells (lx 106 cells/mouse) were injected s.c. into the right hind legs of
C57BL/6 mice and allowed to become established for 12-14 days, at which time the
tumors were measurable (—200-300 mm3). Treatment was then initiated using different
doses of pXLG-mEndo that were injected intratumorally. The pWS4 empty vector or
PBS was used in the control groups. A dose of 10 Gy of y-radiation (60Co) was applied 16
hrs after plasmid injection. Additional treatments were applied in subsequent aims.
Specific aim 1: Analyze the kinetics of pXLG-mEndo expression in Lewis lung
tumors with time after injection
The intent of this aim was to determine the length of time that pXLG-mEndo
would be expressed after intratumoral injection. This was an important aspect of the
study in that the results would be used to help design subsequent experiments in which
multiple injections would be administered. If a very rapid and brief expression period was
observed, a short time interval between injections would be indicated, whereas a long and
sustained period of expression would indicate that long time intervals between injections
could be implemented.
A single dose of 100 pg of pXLG-mEndo was used in this kinetic study. Selection
of the dose was based on our previous experience with the same pWS4 vector carrying
different genes (Gridley et al., 2000, 2002a, 2002b, 2003; Li et ah, 1998), as well as the
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Sequence of experiment events:

1 x 106 LLC cells
injection

i

Plasmid injection

i

12-14 days

10 Gy y-ray irradiation

16 hours

i

Figure 4.8.
Sequence of experiment events in animal studies. LLC: Lewis
lung carcinoma.
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dose range reported by other investigators (Ding et al, 2001; Szary et al., 2001;
Blezinger et al., 1999; Chen, 1999). Mice were euthanized every other day from day 1
until day 11 after plasmid injection. Euthanasia was performed in 100% CO2, a procedure
that complies with the recommendations of the American Veterinary Association Panel
on Euthanasia. At euthanasia, whole blood was collected by cardiac puncture and
evaluated by automated hematology analyzer. Plasma was collected after the analysis.
Tumors were weighed, minced, and processed. Tumor supernatants and plasma were
tested for mouse endostatin by ELISA. In addition, this work provided an opportunity to
obtain baseline level of VEGF during progressive EEC tumor growth.
The time-course of tumor endostatin and VEGF is shown in Figure 4.9. There was
an expression peak for both tumor endostatin (167.24 ng/g) and tumor VEGF (64.62
ng/g) on day 7 after injection of the plasmid. The expression levels of both tumor
endostatin and VEGF were significantly higher than at all the other time points (days 1,
3, 5, 9, and 11) of testing (p<0.05). Furthermore, there was a trend toward decreasing
levels after day 7 for both tumor endostatin and VEGF. There were no significant
differences for both plasma endostatin and VEGF between each treatment group (data not
shown).
Specific aim 2: Determine the optimal injection dose in combination with radiation
by quantifying the expression of pXLG-mEndo and levels of pro-angiogenic factors
in Lewis lung tumors
After the expression peak on day 7 was obtained, different doses (0, 50, 100, 200,
and 400 pg) of pXLG-mEndo were injected intratumorally. We chose to also apply 10
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Figure 4.9. Time course study of tumor endostatin and VEGF (n=6).
Tumor endostatin and vascular endothelial growth factor (VEGF) expression on
the seventh day after pXLG-mEndo injection was significantly higher than at all
the other time points (days 1, 3, 5, 9 and 11 after plasmid injection). * p<0.05.
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Gy of Co60 radiation at 16 hrs after the plasmid injection. This was done to determine
whether radiation would alter the peak expression time and/or the level of endostatin
expressed within the tumor. There were 6 groups (n = 6 mice/ group). Blood and tumor
samples were collected on day 7 after the plasmid injection as described in Materials and
Methods (Chapter Two). Levels of endostatin and VEGF in both plasma and tumor were
again tested by the ELISA method. Expression of tumor endostatin and VEGF on the
seventh day after plasmid injection +10 Gy y-ray irradiation is shown in Figure 4.10. The
group treated with 100 pg of pXLG-mEndo + 10 Gy had the highest expression level of
tumor endostatin (149.84 ng/g). Tumor endostatin expression in the 100 pg pXLGmEndo + 10 Gy group was significantly higher than in the 400 pg pXLG-mEndo +10
Gy, no plasmid + 10 Gy control, and the no treatment control groups (p<0.05). In
addition, tumor VEGF expression in the 100 pg pXLG-mEndo + 10 Gy group (10.38
ng/g) was significantly higher than in all the other groups including 0, 50, 200, and 400
pg of pXLG-mEndo + 10 Gy y-ray irradiation and no treatment control (p<0.05).
Although tumor endostatin expression in the 50 pg and 100 pg of pXLG-mEndo + 10 Gy
did not show significant difference, the reason is likely to be the lack of statistical power
due to small sample size. Because there was a significant difference for tumor VEGF
level between 50 pg and 100 pg of pXLG-mEndo + 10 Gy, we chose 100 pg of pXLGmEndo as our treatment dose. In addition, we also decided to deliver a boost injection on
the seventh day after the plasmid injection in the subsequent animal studies. There were
no significant differences for both plasma endostatin and VEGF between each group
(data not shown).
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Figure 4.10. Tumor endostatin & VEGF expression on the seventh day
after different doses of pXLG-mEndo injection and irradiation with 10
Gy 60Co 16 hrs later (n=6). A 100 pg dose of pXLG-mEndo was used. The
group injected with pXLG-mEndo had the highest expression of both tumor
endostatin and vascular endothelial growth factor (VEGF). The amount of
VEGF in tumors injected with pXLG-mEndo was significantly higher than in
all other groups. Tumor endostatin level in the pXLG-mEndo group was
significantly higher than in the groups injected with 0 and 400 pg of pXLGmEndo and in the no treatment control group. * p<0.05.
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Specific aim 3: Evaluate tumor progression and anti-angiogenesis effects following
single and multiple injections of pXLG-mEndo with and without radiation
Although plasmids injected directly into target tissue have relatively stable
expression for a longer period of time compared to proteins, they will still be degraded
gradually after administration. Based on the results from our time-course studies of
endostatin and pro-angiogenic factors in in vivo specific aims 1 and 2, we decided to
apply the combination treatments twice. In part I of this specific aim, we evaluated one
time combination treatment with pXLG-mEndo + radiation to confirm that pXLG-mEndo
enhances the inhibitory effect of radiation on tumor growth in the EEC animal model. In
Part II of this aim we focused on directly comparing the inhibition effects between one
time and two-time combination treatments.
Part I: confirm difference in tumor progression following single injection of
pXLG-mEndo with and without radiation. In this study, the animal groups (n = 6/group)
included: no treatment, pXLG-mEndo only, radiation only, and combination treatment
with pXLG-mEndo plus radiation. pXLG-mEndo was used at 100 pg as the optimal
treatment dose and 10 Gy of Co60 irradiation was applied 16 hrs later. Mouse body
weights were recorded and animals were observed every day for signs of toxicity after
treatment initiation. Tumor dimensions were measured every day with vernier calipers,
and volumes were calculated: tumor volume (mm ) = (height x width x length)/2. The
tumor growth curves for each group are shown in Figure 4.11. Combination treatment
with pXLG-mEndo and radiation had significantly higher inhibitory effects on tumor
growth than the untreated control and all other treatment groups (p<0.05) from day 8 to
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Figure 4.11. Anti-tumor effects of pXLG-mEndo and radiation.
Combination treatment with pXLG-mEndo (100 pg) plus radiation (10
Gy 60Co) resulted in significantly smaller tumor volumes than in all
other groups from days 8-11 after plasmid injection. *p<0.05.
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day 11 after injection of the plasmid. All mice were euthanized when average tumor
volume in one of the groups reached -2000 mm3. This clearly suggests that combination
treatment with pXLG-mEndo and radiation had stronger inhibition effects on tumor
growth than either pXLG-mEndo treatment or radiation treatment alone.
Part II: evaluate tumor progression following single and two-time combination
treatments with pXLG-mEndo and radiation. This study was focused on comparing the
degree of tumor inhibition between single and multiple combination treatments. The 6
groups (n = 8 mice/group) were: 1) pXLG-mEndo, two treatments; 2) radiation, two
treatments; 3) pWS4 plus radiation, two treatments with each modality; 4) pXLG-mEndo
plus radiation, one treatment with each modality; 5) pXLG-mEndo, two treatments with
each modality; and 6) no treatment. pXLG-mEndo was applied as the optimal injection
dose of 100 pg and 10 Gy Co60 irradiation was performed 16 hrs after the plasmid
injection as described previously in the Sequence of Experiment Events’ section. The
second set of combination treatments was initiated on the seventh day after the first
plasmid injection. All mice in a group were also euthanized when average tumor volume
in that group reached -2000 mm3. Figure 4.12 shows the tumor growth curves for each
group in this study. Two-time combination treatments with pXLG-mEndo and radiation
significantly increased the inhibition effect on EEC tumor growth from day 9 to day 13
after the first plasmid injection, compared to all the other treatment groups (p<0.05).
Except the two-time combination treatment group with pXLG-mEndo plus radiation,
mice in the other five groups were all euthanized on day 13 after the first plasmid
injection. While the average tumor volume in the pXLG-mEndo plus radiation group that
received both modalities twice was still below 1500 mm3 on day 14 after the first plasmid
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Figure 4.12. Anti-tumor effects of pXLG-mEndo and radiation. A
dose of 10 Gy 60Co radiation was applied 16 hrs after injecting 100 fig of
the plasmid. One group received a second set of combination treatments
on day 7 and day 8 (6-7 days after the first treatments). The group
receiving combination treatment twice exhibited the slowest tumor growth
compared to all other groups during days 9-15 after the first plasmid
injection. *p<0.05.
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injection. Figure 4.13 shows same tumor growth data as in Figure 4.12, but it emphasizes
the difference between one-time and two-time combination treatment with pXLG-mEndo
and radiation. Compared to one-time combination treatment, two-time treatment with
pXLG-mEndo plus radiation had significantly smaller EEC tumor volumes (p<0.05)
beginning on the ninth day after the first plasmid injection (one day after the last
treatment) until the 13th day, when the mice in the one-time combination treatment group
were euthanized because the average tumor volume had reached -2000 mm . These
findings confirmed the greater tumor inhibition effects of two-time combination
treatment in our study and we used it as our optimal experimental design for the
subsequent animal studies to further investigate cytokine and cellular changes resulting
from combination treatment.
Specific aim 4: Quantify effects of multiple combination treatments with pXLGmEndo and radiation on cytokines associated with angiogenesis and leukocytes with
anti-tumor activities
In this aim, the animal number in each group was increased to 10 in order to
improve the possibility for obtaining statistically significant differences among groups.
pXLG-mEndo was administered at 100 pg as the optimal plasmid injection dose. An
equal amount of pWS4 empty vector or PBS was used in the control groups and 10 Gy
60Co radiation was delivered 16 hrs later. Except for the no tumor and no treatment
control groups, all mice received two sets of treatments, with the second set being
initiated on the seventh day after the first plasmid injection. The animals were assigned to
seven groups as follows: 1) no tumor control; 2) no treatment control; 3)
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Figure 4.13. Anti-tumor effects of pXLG-mEndo and radiation.
Administering the combination treatment of 100 (o.g pXLG-mEndo
and 10 Gy radiation twice resulted in significantly greater inhibition
of Lewis lung tumor growth than when each modality was delivered
only once. *p<0.05.
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pWS4; 4) pXLG-mEndo; 5) radiation; 6) pWS4 plus radiation; and 7) pXLG-mEndo
plus radiation. All of the mice except the no tumor control group had a subset of animals
which were euthanized simultaneously at one day after the last treatment (“short-term”
mice) for in vitro analyses. The remaining mice were kept long-term so that tumor
growth could be monitored (“long-term” mice). A total of 130 animals were used in this
aim. The short-term mice were euthanized on day 9 after the first plasmid injection (i.e.,
one day after the last treatment). Blood and tumor samples were collected as described
previously. Whole blood was tested by automated hematology analyzer and flow
cytometry equipment to determine whether the combination treatments resulted in
measurable hematological toxicity and to assess the quantities of major leukocyte
populations (some of which are responsible for secreting angiogenic factors). Plasma was
collected after the whole blood analyses. The expression of endostatin, VEGF, and TGFP1 in both plasma and tumor were tested by the ELISA method. Spleen samples were
also collected at the time of euthanasia and processed using RBC lysing and unlysing
procedures so that leukocytes could be evaluated using the automated hematology
analyzer and the flow cytometer. Activated spleen leukocytes were also evaluated for
production of selected cytokines using the CBA technique and flow cytometry. All of the
specific procedures utilized are described in the Materials and Methods (Chapter Two).
The long-term mice were euthanized individually when the tumor volume for each mouse
reached -2000 mm3. Tumor sections from long-term mice were stained by anti-CD31
immunohistochemistry in order to characterize tumor blood vessel densities.
Tumor growth curves obtained for each group of long-time mice in this last aim
are shown in Figure 4.14. Treatment with the pWS4 empty vector alone did not have any
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Figure 4.14. Anti-tumor effects of pXLG-mEndo and radiation.
Administering the combination treatment of 100 jag pXLG-mEndo plus
10 Gy radiation twice resulted in the greatest inhibition of Lewis lung
tumor growth compared to all other experimental groups from days 915 after the first plasmid injection. *p<0.05.
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effect on tumor growth compared to the tumor-bearing mice receiving no treatment.
Groups treated with radiation alone, pXLG-mEndo alone, and pWS4 plus radiation had
significantly smaller tumors from day 5 to day 10 after the first plasmid injection
compared to the groups given no treatment or only pWS4 (p<0.05). The combination of
pXLG-mEndo with radiation resulted in the slowest tumor growth, with tumor volumes
from day 9 to day 14 after the first plasmid injection being significantly smaller
compared to all the other experimental groups (p<0.05). In addition, as shown in Table
4.1, the anti-tumor effects of combined therapy were greater than additive on days 8 and
9.
CD31 is a ~130 kDa integral membrane protein expressed on the surface of adult
and embryonic endothelial cells. CD31-mediated endothelial cell-cell interactions are
involved in angiogenesis. Anti-CD31 immunohistochemical staining of endothelial cells
can be used to demonstrate tumor vessel density. In this study, less than 3 mm thickness
freshly cut tumor pieces were specially fixed in zinc fixative instead of regular formalin
fixative in order to get rid of high background and false positive results. After fixation,
tumor samples were processed and paraffin embedded. Five-micron serial sections were
then cut by microtome for immunohistochemistry (IHC), after which measurement of
tumor vessels was made. A total of five high-power fields (400 x) per section were
examined by Olympus microscope equipped with a Roper Scientific digital camera as
described in detail in Materials and Methods (Chapter Two). Tumor vessel densities were
measured by Image-Pro® imaging software. Tumor sections labeled with anti-CD31
antibodies are shown in Figure 4.15. Brown color cells are indicative of labeling for the
positive endothelial cells, demonstrating the tumor microvasculature. As shown in Table
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Inhibition effect of combining pXLG-mEndo and ionizing radiation
Table 4.1.
on Lewis lung carcinoma growth.

Fractional tumor volume relative to untreated controls
Day”

pXLGmEndo

73,Co~
radiation

Combined
(expected)0

Combined
(observed)

Observed/
expectedd

8

0.778

0.691

0.537

0.509

0.947

9

0.847

0.676

0.573

0.544

0.949

10

0.755

0.661

0.499

0.502

1.005

a Obtained by dividing the mean volume of treated tumors by untreated controls.
The day after the first plasmid injection.
cObtained by multiplying the fractional tumor volumes obtained by each treatment
modality individually to yield the fractional tumor volume expected if the effects of each
treatment modality were additive.
dObtained by dividing the observed fractional tumor volumes by the expected fractional
tumor volume. A ratio <1 indicates a greater than additive effect, and a ratio > 1 indicates
a less than additive effect (Gorski et al., 1999).
Effects of combination treatment were greater than additive for LLC on days 8 and 9
after the first plasmid injection and almost equal to additive on day 10. From days 11-13,
we cannot calculate the observed combined effects because the mice in the group
receiving treatment with pXLG-mEndo alone had to be euthanized since the mean tumor
volume had reached the 2000 mm3 maximum allowed. After day 14, only mice in the
combination treatment group were still alive. These calculations were performed to
determine whether combination treatment produced additive or synergistic effects.
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No treatment

pXLG-mEndo

Radiation

pXLG-mEndo + Radiation

Figure 4.15. Visualization of the tumor vasculature using anti-CD31
immunohistochemistry (1HC). Tumor vessel density in the group
treated with the combination of 100 pg pXLG-mEndo and 10 Gy
radiation was significantly less than groups receiving radiation only,
pXLG-mEndo only, and no treatment (p<0.05). Tumor samples were
collected when the tumor volume reached -2000 mm3.
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4.2, tumor vessel density was significantly lower in the combination treatment group of
pXLG-mEndo plus radiation (11 ±6) compared to either pXLG-mEndo alone (34 ± 10)
or no treatment (60 ± 8) (p<0.05 for both comparisons). These data suggest an interaction
between pXLG-mEndo (endostatin) and radiation.
To better understand the effect of multiple combination treatments on tumor
angiogenesis in our LEG animal model, the levels of endostatin and important proangiogenic factors were quantified in both plasma and tumor supernatant. As shown in
Figure 4.16a, the concentration of tumor endostatin was significantly higher in the group
receiving pXLG-mEndo than in tumors from the pWS4 treated mice and the PBS control
group (p<0.001). Tumors injected with pXLG-mEndo and irradiated with 10 Gy 60Co
also had significantly increased endostatin (p<0.001). Indeed, the combination treatment
group had the highest tumor endostatin level (192.2 ng/g) among all the animal groups
(p<0.05). Based on ANOVA, there was an interactive effect between plasmid and
radiation (pO.OOl) and a trend for effect of radiation (p=0.081). Figure 4.16b shows that
plasma endostatin level was also significantly higher in pXLG-mEndo treated mice
compared to pWS4 empty vector and PBS treated mice (pO.OOl). These data correlated
with the tumor volume and tumor vasculature results. Finally, plasma endostatin level
was significantly higher in the mice received pXLG-mEndo ± Radiation compared to the
normal mice with no tumor (p <0.001). The pro-angiogenic factor VEGF was
significantly increased within irradiated tumors compared to the non-irradiated tumors
(pO.Ol) (Figure 4.17a). In addition, the pXLG-mEndo plus radiation treated mice had
the highest tumor VEGF level (8.48 ng/g, pO.Ol compared to all the other groups).
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Microvessel density in Lewis lung carcinoma3. pXLG-mEndo and yTable 4.2.
radiation were each delivered twice (100 pg x 2 and 10 Gy x 2 respectively). Tumor
tissue sections were examined by use of anti-CD31 antibody and standard
immunohistochemical techniques.

Treatment

Microvessel Count*

No treatment

60 ±8

pXLG-mEndo

34± 10

pXLG-mEndo + IR

11 ±6b

^Numbers represent the mean +/- SEM for 6 tumors/group.
IR: ionizing radiation.
aTumor samples were collected when tumor volume reached -2000 mm3.
bp<0.05 versus other two groups.
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T trend for effect of radiation (p=0.081)

Figure 4.16. Endostatin expression in tumor and plasma one day after
the last combination treatment. Tumors were injected with 100 (ig pXLGmEndo or pWS4 and exposed to 10 Gy radiation 16 hrs thereafter. This
procedure was repeated 6 days later.
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Figure 4.17. Vascular endothelial growth factor (VEGF) expression in
tumor and plasma one day after the last combination treatment.
Tumors were injected with 100 |ag pXLG-mEndo or pWS4 and exposed to
10 Gy radiation 16 hrs thereafter. This procedure was repeated 6 days later.

90

There was also a trend for an effect of plasmid (p=0.064) and a trend for plasmid and
radiation interaction (p=0.089). Plasma VEGF level (shown in Figure 4.17b) was
significantly increased in tumor-bearing mice only when compared with the no tumor
controls (p<0.001). There were no significant differences between the treatment groups
based on the Tukey test (p>0.05). TGF-pl also plays an important role in angiogenesis.
Tumor TGF-pi expression (shown in Figure 4.18a) was significantly higher in pXLGmEndo treated mice than in pWS4 and PBS treated mice (p<0.05). In addition, there was
a trend for effect of radiation (p<0.052). For plasma TGF-pi (Figure 4.18b), irradiation
with 20 Gy 60Co significantly increased the level of this factor compared to non-irradiated
controls (p<0.001). There was also an interactive effect between plasmid and radiation
(p<0.05). All of the tumor-bearing mice had a significantly higher TGF-pl concentration
than did the mice with no tumor (p <0.001).
For the hematological analysis by HESKA machine (shown in Table 4.3), there
were significant differences for RBC, HCT, HGB, PET, and MPV only between tumor
bearing mice and no tumor controls (p<0.05 or less). Presence of tumor was associated
with anemia and thrombocytopenia. Injection of plasmid, either pWS4 or pXLG-mEndo,
had some effect on platelet counts and volume, but the effects were very small, and
showed up only when the data were combined and analyzed by two-way ANOVA. For
all the other factors (MCV, MCH, MCHC, and RDW), there were no significant
differences found. Based on these data, pXLG-mEndo gene therapy and radiotherapy did
not show obvious hematological toxicity in the EEC mouse model.
The effect of y-radiation and endostatin gene therapy on the three major
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Figure 4.18. Transforming growth factor |31 (TGF-pl) expression in
tumor and plasma one day after the last combination treatment (the 9th
day after first plasmid injection). Tumors were injected with 100 jiig
pXLG-mEndo or pWS4 and exposed to 10 Gy radiation 16 hrs thereafter.
This procedure was repeated 6 days later.
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Effects of gamma irradiation and endostatin gene therapy on blood
Table 4.3.
characteristics one day after last combination treatment. Tumors were injected with
100 pg pXLG-mEndo or pWS4 and exposed to 10 Gy radiation 16 hrs thereafter. This
procedure was repeated 6 days later.

Tumor-bearing
pXLGmEndo+
Radiation

No
tumor

No
treatment

RBC

8.18±0.32

4.53±0.39a

HCT

39.61±0.79 23.20±1.13a 27.84±3.06a 25.60±2.02a 24.41±1.97a 25.00±1.24a 24.67±0.99

HGB

12.32±0.29 7.53±0.42a 8.84±0.96b 8.12±0.65a 7.90±0.67a 7.92±0.44a 7.97±0.33

PLTf

620.1±32.1 288.9±28.3a 377.1±25.4a 350.9±29.3a 285.4±18.0a 362.6±25.4a 325.3±17.6

MPV+

8.38±0.24

BLOOD

pXLGmEndo

pWS4

Radiation

pWS4+
Radiation

5.31±0.98c 5.47±0.44c 5.20±0.46a 4.81±0.49a 4.85±0.48

11.33±0.37a 9.86±0.30

10.08±0.60 11.28±0.43a 10.21±0.39c 10.42±0.29b

Two-way ANOVA: f p<0.05 or p<0.001 for main effect of plasmid (pWS4 and pXLGmEndo).
Tukeys:a p<0.001, bp<0.005, or cp<0.05 versus no tumor controls.
RBC (107ml): red blood cell count; HCT (%): hematocrit; HGB (g/dl): hemoglobin; PLT
(10 /mm ): platelet count; MPV (fl): mean platelet volume.
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leukocyte populations at one day after the last combination treatment is shown in Table
4.4. For blood leukocytes, based on two-way ANOVA, radiation had an effect on
numbers of total WBC, lymphocytes, monocytes, and granulocytes, and on the
percentage of lymphocytes and granulocytes (p<0.05 or less). In general, although all
tumor-bearing groups had an increased WBC count in the blood with respect to normal
mice without tumor, those receiving radiation had lower numbers of cells compared to
the non-irradiated groups. The depressive effect of radiation was especially evident on
the lymphocytes. For spleen leukocytes, two-way ANOVA revealed that both plasmid
and radiation had effects on the numbers of total WBC, monocytes, and granulocytes, as
well as on the percentage of lymphocytes (p<0.05 or less). However, there was no effect
for either radiation or plasmid on the percentage of monocytes. In contrast to the blood,
the total WBC counts in the spleen were elevated only in the tumor-bearing group
receiving no treatment. However, as in the blood, lymphocyte numbers were lowest in the
irradiated groups.
Since lymphocytes are especially important in tumor surveillance, often infiltrate
tumor masses, and secrete at least some cytokines that are associated with angiogenesis,
subsets of these cells were quantified by flow cytometry analysis (Table 4.5). In the
blood, two-way ANOVA indicated that radiation had an effect on the numbers of B220+
B cells, CD3+, CD4+, and CD8+ T cells, and the CD4:CD8 T cell ratio (p<0.05 or less).
It also had an effect on the percentage of CD3+, CD4+ T cells, and NK1.1+ NK cells
(p<0.05 or less). The B cells were most affected by radiation, with all irradiated groups
having lower numbers than the group with no tumor. In the non-irradiated tumor-bearing
groups, B cell counts were well above normal. A different pattern was noted for the T
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Effects of gamma radiation and endostatin gene therapy on
Table 4.4.
lymphocytes, monocytes, and granulocytes one day after last combination
treatment. Tumors were injected with 100 jag pXLG-mEndo or pWS4 and exposed to 10
Gy radiation 16 hrs thereafter. This procedure was repeated 6 days later.

Tumor-bearing

BLOOD

No
tumor

No
treatment

pXLGmEndo

pWS4

Radiation

pWS4+
Radiation

pXLGmEndo+
Radiation

#WBC*

4.32±0.69

19.98±1.81 21.88±1.84 21.42±2.67 6.63±0.75

7.01±1.01

6.96±0.68

#Lymph*

2.61±0.45

4.66±0.55

4.80±0.42

4.85±0.79

1.30±0.39

1,42±0.34

1.34±0.29

#Mono*

0.34±0.04

0.80±0.08

0.82±0.07

0.83±0.09

0.20±0.03

0.25±0.04

0.23±0.03

#Gran*

1.37±0.20

14.51±1.35

16.26±1.46

15.73±1.79 5.13±0.61

5.50±0.83

5.38±0.56

%Lymph

60.74±1.06 23.50±1.79 22.34±1.14 22.38±0.90

16.98±0.77

19.69±2.21

17.72±2.27

%Mono

9.9±0.57

3.63±0.31

4.30±0.27

3.96±0.30

%Gran*

29.36±0.84 72.24±1.91

4.26±0.15

3.84±0.15

4.10±0.16

73.62±1.24 73.52±0.90 80.50±1.54 76.0U2.45 76.10±3.50

SPLEEN
#WBC*n

28.73±2.58 56.65±6.19 25.20±1.30 33.97±1.07 22.62±2.30 24.64±2.59 25.18±2.27

#Lymph*t

20.04±1.67 26.80±2.66

17.52±2.57 21.83±1.50 9.44±0.79

#Mono+n

2.29±0.21

3.55±0.12

1.68±0.15

#Gran *+*

6.4±0.73

34.35±4.76 9.00±0.71

11.96±1.64

11.20±1.05

3.23±0.32

1.52±0.16

1.64±0.20

1.56±0.14

23.90±2.10

11.46±1.04

12.04±1.26

12.53±1.16

%Lymph*n 70.6U0.85 44.49±2.04 53.54±3.28 44.95±1.68 43.19±1.96 43.25±0.84 44.46±0.87
6.99±0.14

7.08±0.24

6.77±0.20

6.60±0.27

6.6U0.21

6.77±0.20

%Mono

8.30±0.16

%Gran*f

21.09±0.85 48.58±2.04 39.38±3.33 48.28±1.69 50.2U2.13 47.84±2.14 48.78±0.83

Two-way ANOVA: * p<0.05 or p<0.001 for main effect of radiation.
+
p<0.05 or p<0.001 for main effect of plasmid (pXLG-mEndo and pWS4).
t p<0.05 or p<0.001 for effect of plasmid x radiation interaction.
WBC (106. ml'1): white blood cells; Mono (106. ml'1): monocytes; Gran (106. ml'1):
granulocytes; Lymph (106. ml'1): lymphocytes.
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Table 4.5.
Effects of gamma-ray irradiation and endostatin gene therapy on
lymphocyte counts and distribution of lymphocyte populations one day after
combination treatments. Tumors were injected with 100 pg pXLG-mEndo or pWS4
and exposed to 10 Gy radiation 16 hrs thereafter. This procedure was repeated 6 days
later.
Two-way ANOVA: * p<0.05 or pO.OOl for main effect of radiation.
^pO.OS or pO.OOl for main effect of plasmid (pXLG-mEndo and pWS4). TTrend
p=0.075.
B220 (106 ml'1): B cells; CDS (106 ml’1) : mature T cells; CD4 (106 ml'1): T helper (Th)
cells; CDS (106 ml'1): T cytotoxic (Tc) cells; NK1.1 (106 ml'1): natural killer cells.
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Tumor-bearing

BLOOD

No
tumor

No
treatment

pXLGmEndo

pWS4

Radiation

pWS4+
Radiation

pXLGmEndo+
Radiation

#B220*

2.00±0.41

8.26±0.86

10.11±0.43 9.52±0.69

1.00±0.21

0.89±0.21

0.97±0.20

#CD3*

1.76±0.20

7.26±0.77

7.70±1.32

8.02±1.29

3.77±0.47

3.77±0.60

3.77±0.38

#CD4*

1.10±0.12

4.14±0.35

4.32±0.72

4.63±0.68

2.53±0.28

2.55±0.40

2.55±0.25

#CD8*

0.5 ±0.08

2.81±0.36

3.05±0.56

3.11±0.58

1.01±0.15

0.90±0.18

1.01±0.11

CD4:CD8*

1.92±0.08

1.52±0.08

1.45±0.06

1.56±0.08

2.67±0.20

2.66±0.13

2.54±0.10

#NK1.1

0.27±0.03

0.80±0.11

1.31±0.32

1.00±0.11

1.00±0.194 0.89±0.16

1.02±0.16

%B220*

46.66±2.39 50.55±2.84 49.33±3.10 46.89±1.89

%CD3*

45.97±1.90 44.38±2.14 43.40±2.53 46.66±1.40 65.67±2.04 68.76±1.96 66.71±1.72

%CD4*

28.82U.37 25.56±1.11 24.63±1.73 27.29±0.90 44.74±1.59 47.17±1.92 45.35±1.64

%CD8

14.99±0.46 17.00±0.78 16.97±0.99 17.7U0.84 18.46±0.64 16.45±0.93 17.95±0.61

%NK1.1*

7.37±0.62

5.07±0.82

7.27±0.88

6.45±0.99

16.20±2.45

14.70±1.60 16.33±1.91

17.68±1.05

17.14±1.00 18.07±1.23

SPLEEN
#B220>

15.5U1.26 34.12±2.99 15.62±1.93 24.84±1.92

10.52±2.71

8.19±1.43

7.89±1.13

#CD3*

9.73±0.99

19.60±2.32

11.46±2.03

13.66±2.79

10.62±1.63

#CD4*

5.54±0.56

10.26±1.18 7.20±2.10

9.33±1.04

6.49±1.11

7.52±1.52

5.94±0.92

#CD8*

3.85±0.43

8.22±0.95

6.04±1.86

6.85±0.85

4.17±0.82

5.05±1.06

3.94±0.61

CD4:CD8*

1.46±0.04

1.25±0.03

1.22±0.03

1.38±0.07

1.60±0.06

1.53±0.04

1.50±0.04

#NK1.1

0.58±0.75

0.96±0.17

0.47±0.18

0.78±0.21

1.16±0.10

0.89±0.25

0.73±0.11

%B220*

60.36±0.89 61.78±1.29 58.73±3.28 58.17±2.31 42.76±2.87 35.05±2.71 41.17±1.51

%CD3*t

37.44±0.85 36.38±1.00 39.95±3.13 40.07±2.28 51.1U2.30 61.39±2.83 55.00±1.64

%CD4*t

21.33±0.44

19.10±0.40 20.69±1.51 21.57±0.99 29.02±1.53 34.17±1.81

%CD8*t

14.73±0.54

15.36±0.59

17.04±1.41

15.86±1.10 18.25±0.90 22.27±0.93 20.08±0.61

%NKl.r

2.2U0.12

1.85±0.39

1.32±0.32

1.77±0.41

14.08±4.26 17.39±2.11
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5.13±0.38

3.56±0.52

31.02±1.25

3.83±0.35

cells. Their numbers (total CD3+ and the CD4+ and CD8+ subsets) were higher in the
blood from tumor-bearing groups, regardless of irradiation, although the enhancement
was less pronounced in the irradiated groups. The high CD4:CD8 ratios in the irradiated
mice, together with the numbers of each subset, indicated that the CD8+ Tc population
was more susceptible to radiation than the CD4+ Th cells. Blood NK cell counts were
elevated by tumor presence and radiation had no measurable effect. For the spleen
lymphocytes, two-way ANOVA indicated that radiation and plasmid had effects on B
cell number, percentage of CD3+ total T cells, and percentage of CD8+ Tc cells (p<0.05
or less). Overall, the pattern of changes seen in the various lymphocyte populations was
similar to what was observed in the blood.
In order to investigate the functional status of Th lymphocytes after different
treatments, the levels of Thl and Th2 cytokines in supernatants from PHA-activated
splenocytes were quantified using the CBA (BD™ cytometric bead array) assay and flow
cytometry. There were no significant differences for Th2 cytokines (IL-4 and IL-5)
among the various groups (data not shown). However, Thl cytokines (IFN and IL-2)
were significantly changed in different treatment groups (p<0.05 or less). The TNF-a
data, presented in Figure 4.19 show that plasmid injection (pWS4 and pXLG-mEndo)
significantly lowered the levels of this cytokine compared to the no plasmid treated
control group (p<0.05). Radiation significantly decreased TNF-a only in the mice
receiving no plasmid (pO.OOl). Mice with no tumor had the highest level of TNF-a
production by splenocytes, with the mean value being significantly higher compared to
the means obtained for all of the tumor-bearing groups (pO.OOl). In the case of IFNy (Figure 4.20), radiation significantly lowered its expression compared to the non-
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Figure 4.19. Mouse Thl/Th2 cytokine CBA analysis (BD1M cytometric bead
array): tumor necrosis factor-a (TNF-a). Tumors were injected with 100 ng
pXLG-mEndo or pWS4 and exposed to 10 Gy radiation 16 hrs thereafter. This
procedure was repeated 6 days later.
* main effect of plasmid (p<0.05)
f main effect of radiation (p<0.005)
% plasmid x radiation interaction (p<0.05)
a. p<0.001 vs no treatment
b. p<0.001 vs all tumor-bearing groups
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Figure 4.20. Mouse Thl/Th2 cytokine CBA analysis (BDTM cytometric bead
array): interferon-y (IFN-y). Tumors were injected with 100 jag pXLG-mEndo or
pWS4 and exposed to 10 Gy radiation 16 hrs thereafter. This procedure was repeated 6
days later.
* main effect of plasmid (p<0.001)
f main effect of radiation (p<0.001)
J plasmid x radiation interaction (p<0.05)
a. p<0.001 vs no radiation
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irradiated mice (p<0.001). Plasmid (pWS4 and pXLG-mEndo) treated mice had
significantly lower spleen IFN-y expression than the group receiving no plasmid
(pO.OOl). Two-way ANOVA indicated that there was also a plasmid and radiation
interaction for IFN-y (p<0.05). IL-2 level (Figure 4.21) was significantly lower in the
pXLG-mEndo treated mice than in the pWS4 treated and no plasmid treated animals
(pO.OOl). In addition, splenocytes from all of the tumor-bearing mice secreted
significantly higher levels of IL-2 than did the cells from the no tumor controls
(pO.OOl).
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Figure 4.21. Mouse Thl/Th2 cytokine CBA analysis (BD1M cytometric bead
array): interleukin2 (IL-2). Tumors were injected with 100 fig pXLG-mEndo or
pWS4 and exposed to 10 Gy radiation 16 hrs thereafter. This procedure was
repeated 6 days later.
* main effect of plasmid (p<0.001)
a. p<0.001 vs all tumor-bearing groups
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CHAPTER FIVE
CONCLUSIONS
Overview
Over the course of time, many significant improvements have been made in
cancer patient survival and quality of life due to advances in radiotherapy regimens.
However, as in the case with other forms of conventional anti-cancer therapies (e.g.,
chemotherapy and surgery), radiation is a local form of treatment lacking tumor
specificity (Wheldon et al., 1998). Even though a radiation dose-response curve has been
documented for most tumors and virtually all neoplastic cells could be destroyed if
exposed to a high enough dose, the increase of radiation doses is limited by the risk for
normal tissue toxicity. In addition, radiation therapy cannot be expected to eradicate
metastatic disease outside of the exposed field. Gene therapy of cancer allows for the
introduction of genetic material that may result in radiosensitization and other means by
which the overall anti-tumor efficiency is enhanced. One specific anti-angiogenic gene
therapy approach is the endostatin gene delivered by our pXLG-mEndo plasmid.
In the present study, the efficacy and potential anti-tumor mechanisms were
investigated after combining pXLG-mEndo mediated endostatin gene therapy with
radiation in a mouse Lewis lung carcinoma model. Lung cancer is the second most
common malignancy for both men and women in the U.S.A. Radiation therapy for local
control is the standard of care for patients electing to have surgery, and chemotherapy is
administered to eliminate occult metastasis, even at the early stages of the disease.
Because these therapies frequently fail to eradicate the disease and are associated with
toxicities (Boehm et al., 1997), the development of novel treatments with radiosensitizing
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and anti-metastatic properties, as well as low risk for toxicity, may prolong disease
control, shorten treatment times, and minimize the possibility for treatment-related side
effects.
The study also assessed whether multiple-course endostatin gene therapy in
combination with radiation could further improve outcome without seriously
compromising animal health. Repeated courses of endostatin gene therapy may be
necessary as a result of the limited efficacy in gene transduction, temporary transgene
expression, and elimination of the vector by cellular and humoral immune mechanisms
(Trapnell et al., 1993; Yang et al., 1994). Because radiation therapy is usually
administered over a time period of weeks, repeated gene therapy injections may be
necessary to achieve a radiosensitizing effect. Moreover, because cancer is a chronic
disease, repeated treatments may prove useful in inducing and maintaining tumor
responses and in treating recurrences.
In vitro Studies
Tumor growth is highly dependent on angiogenesis. Blood vessel formation is the
lifeline of solid tumors. Endostatin, the 20 kDa C-terminal domain of collagen XVIII, is a
potent angiogenesis inhibitor. Its administration has been associated with little or no risk
for development of resistance and toxicity. We initiated our study by synthesizing a
plasmid vector expressing the endostatin gene (pXLG-mEndo). A universal eukaryotic
expression vector, pWS4, was selected for endostatin gene insertion, based on its high
expression efficiency that has been proved. Plasmid pXLG-mEndo (4614 bp),
constructed in our laboratory, contains a mouse endostatin gene that is under the control
of a CMV promoter. The secretion property of the protein is accomplished by a leader
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secretory sequence upstream of the gene. The construction of pXLG-mEndo was
confirmed by DNA sequencing and gel electrophoresis analysis. The expressed
endostatin protein in LLC cells was tested by western blot analysis. LLC cells transfected
with pXLG-mEndo expressed a single band representing a 20 kDa protein that was the
correct size for endostatin, while the LLC cells transfected with the empty vector pWS4
did not express any protein.
Expression of the construct was tested, both with and without radiation, also using
the LLC cell line. In vitro ELISA and immunocytochemical analysis for the therapeutic
gene demonstrated that the expression of the protein was not in the transfected LLC cell
plasma, but in the conditioned medium. In addition, in the time course study of
endostatin expression in LLC cells, for non-irradiated cells, the expression peak of
endostatin protein (13.6 ng/ml) was on day 3 after transfection. For irradiated cells, the
expression peak (16.7 ng/ml) was on day 2 after transfection. The peak level of
endostatin produced by the irradiated cells was significantly higher than that of their nonirradiated counterparts at several consecutive time points. In addition, the time to reach
peak level was also shortened about one day in irradiated LLC cells. These findings
indicated that radiation significantly enhanced the expression of pXLG-mEndo.
Functionality of the expressed endostatin was then tested in vitro utilizing an
angiogenesis system-endothelial cell tube formation assay. Tube formation is one of the
important stages in angiogenesis after endothelial cell proliferation and migration. Tube
formation was inhibited in endothelial cells (HUVEC) treated with supernatants from
pXLG-mEndo transfected HUVEC cells, compared to control cultures receiving either no
treatment or the pWS4 empty vector. These results demonstrated that the protein
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expressed by plasmid pXLG-mEndo had an inhibitory effect on the architectural
organization of endothelial cells during vasculature development.
Furthermore, function of the protein derived from pXLG-mEndo was tested using
both HUVEC and EEC cells. Based on 3H-thymidine incorporation into DNA, the
endostatin gene alone resulted in highly significant depression in HUVEC and EEC cell
growth compared to cells treated with the pWS4 vector and the non-treated controls. In
addition, radiation increased the ability of endostatin to inhibit HUVEC and EEC cell
growth over a 3-day period after exposure. Endostatin binds to the receptors on the
surface of endothelial cells and thus inhibits their proliferation and migration through a
cellular tyrosine-kinase pathway. It is also believed to induce the apoptosis of endothelial
cells. Very little information is available regarding the direct effects of endostatin on
tumor cells. However, there are several reports indicating that endostatin’s anti-tumor
effect may extend beyond its angiostatic/angiocidal properties (Wilson et al. 2003). It can
control VEGF production by endothelial cells or by tumor cells themselves. Taken
together, endostatin can deliver intracellular signals to antagonize pro-angiogenic activity
and probably to down-regulate VEGF expression (Hajitou et al., 2002). Based on our
experimental data, as well as reports by some other investigators, it appears possible that
endostatin may also induce the apoptosis of tumor cells (Dixelius et al., 2003; Streck et
al., 2004; Dkhissi et al., 2003). However, the specific mechanism(s) involved in direct
anti-tumor effects have not yet been well defined and still need further investigation.
Collectively, these findings suggest that endostatin gene therapy may enhance the
efficacy of lung tumor treatment with radiation.
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Animal Studies
In our study, LLC cells were injected s.c. into the right hind legs of C57BL/6
mice and allowed to become established for 10-14 days until the tumors were measurable
(-200-300 mm3). Different doses of plasmids were injected intratumorally and 10 Gy of
60Co radiation was applied 16 hrs later. In the time course study of endostatin and VEGF,
we demonstrated that on day 7 after the plasmid injection, mice had the highest
expression for both endostatin and VEGF within the tumor sites compared to all the other
time points (day 1, 3, 5, 9, and 11 after plasmid injection). Furthermore, we showed that
the 100 pg of pXLG-mEndo resulted in the highest expression of both tumor endostatin
and VEGF on the seventh day after injection. There was no significant difference for
tumor endostatin expression between 50 pg and 100 pg pXLG-mEndo. The reason for
the lack of significant difference between these two doses may be due to small sample
size. Injection of 400 pg did not result in a significantly increased endostatin level
compared to 100 pg, suggesting that the lower dose may already be at or close to the
maximum production capacity in the LLC model. Based on these data, we chose 100 pg
of pXLG-mEndo as our optimal dose and the sixth day after plasmid injection as the time
to deliver a booster injection in the further animal experiments.
In our study, although a single application of either radiation alone or pXLGmEndo gene therapy alone had significant inhibitory effects on tumor growth, delivery of
both modalities twice resulted in a greater than additive anti-tumor effect. The greater
tumor inhibition was related to a decreased number of LLC tumor vessels compared with
exposure to all other treatments. As for the expression of endostatin and angiogenesis
factors, the highest concentration of endostatin was found within tumors from the groups
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treated with pXLG-mEndo plus radiation or pXLG-mEndo alone. A similar pattern was
noted for plasma endostatin. Tumor VEGF concentrations were significantly higher in
the pXLG-mEndo with radiation group compared to all others. All groups with tumor,
except the one treated with pWS4, had significantly elevated plasma TGF-(31 compared
to controls. Highest concentrations were obtained in the irradiated groups with or without
plasmid, and in the group receiving pXLG-mEndo. These data demonstrate that pXLGmEndo can significantly enhance radiation-mediated control of EEC growth, high levels
of endostatin gene expression can be attained in tumors treated with pXLG-mEndo either
with or without radiation, and the measurement of selected regulatory factors (e.g.,
endostatin) in peripheral blood may predict the efficacy of treatment. In addition, based
on hematological analysis, there was no obvious toxicity associated with endostatin gene
therapy and radiation therapy even when both modalities were delivered multiple times.
As for the tumor VEGF level, it was significantly elevated in the combination treatment
group. This result was kind of contradictory to the proposed mechanism of endostatin in
Chapter one (Figure 1.7). Clinical trials have shown that NSCLC patients with high
NSCLC tissue VEGF concentration after treatments are associated with a poor prognosis
(Iwasaki et al., 2004). In addition, breast cancer patients with both normalized serum
VEGF and elevated endostatin following surgery correlated with a lower risk of relapse
than when the VEGF failed to normalize (Zhao et al., 2004). The possible reason for our
findings is that we checked the levels of pro- and anti-angiogenic factors at only one time
point (one day after the last treatment). Since the tumor was not completely eradicated, it
is not entirely surprising that the VEGF level had not decreased to normal at this time of
testing. Long-term effects on these factors need to be further investigated.
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The effects of multiple doses of combination therapy on leukocyte populations
with known anti-tumor properties were also investigated shortly after the last treatment
(referred to as the “short-term” mice). Presence of the tumor induced a dramatic increase
in all three major leukocyte populations (lymphocytes, monocytes, and granulocytes),
with the effect being greater in the blood than in the spleen. Although it was tumorlocalized, radiation significantly decreased the total WBC count; lymphocyte and
monocyte (but not granulocyte) numbers were below normal at the time of testing in both
the blood and spleen. Plasmids (pWS4 and pXLG-mEndo) also had some effects on
leukocyte numbers and distribution, but these were much less pronounced compared to
the influence of radiation. Further analysis of lymphocyte subpopulations revealed that
spleen B cell number and T cell distribution were affected by radiation and plasmid
injection. Overall, the effect of radiation was more evident than that of the plasmids and
the depressive effect of radiation on B cells was more striking than on T cells. Radiation
also shifted the balance of the two major T cell subsets, resulting in a significantly
increased Th:Tc (i.e., CD4:CD8) ratio in both the blood and spleen. In contrast, radiation
and plasmid injections had little or no effect on NK cells in these two body compartments
at the time of testing. Production of TNF-a and IFN-y by splenocytes was significantly
decreased in the mice treated with pXLG-mEndo with or without radiation. Splenocytes
from all of the tumor-bearing mice produced significantly higher levels of IL-2 than did
cells from the controls with no tumor. The long-term effects of radiation and gene
therapy on immunological parameters remain to be investigated in order to better
understand immune status after combination therapies and also to determine whether the
observed changes correlate with treatment outcome.
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In conclusion, these data demonstrate that delivery of endostatin via pXLGmEndo as an adjuvant to radiation can significantly enhance the anti-tumor efficacy of
radiation therapy in the LLC mouse tumor model. The radiation sensitizing/enhancing
effect of pXLG-mEndo most likely occurs through multiple routes, rather than through
any single pathway. Mechanisms supported by the presented data include disruption of
blood vessel formation and direct inhibition of Lewis lung tumor cell proliferation due to
pXLG-mEndo expression. In addition, radiation increased the level of endostatin in
pXLG-mEndo injected tumors, thereby enhancing the efficacy of the anti-angiogenic
therapy. Thus, in this context the two modalities had mutually beneficial effects (Figure
5.1). The high levels of tumor VEGF following administration of pXLG-mEndo together
with radiation may well signal an effort to counteract the hypoxia generated by the
combination treatment. Combination treatment also resulted in relatively low levels of
TNF-oc and IFN-y production by splenocytes. Since both of these anti-angiogenic factors
(although TNF-a can at times be pro-angiogenic) can be secreted by tumor-infiltrating
cells of the immune system, the data suggest that treatment may have resulted in
recruitment of these cells to the tumor sites. Further investigation of this unique
combination therapy appears warranted.
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Figure 5.1. Rationale for anti-tumor effects of combination
treatment with radiotherapy and gene therapy.
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CHAPTER SIX
DISCUSSION
Gene Therapy
Overview
Gene therapy promises to be a singular advance in the treatment of both acquired
and genetic disease at the most fundamental levels of pathology. The use of
polynucleotides for treatment offers many advantages over the use of conventional small
drug molecules. Selective effects are easier to achieve with polynucleotides given their
higher information content. Polynucleotides are generally more stable than small
molecules, thereby enabling more flexible dosing schedules. The inherent stability of
DNA promises that ‘cures’ could be achieved with relatively few administrations or
procedures. Despite this great promise, the challenging problem of efficiently transferring
and stably expressing transgenes in appropriate tissue needs to be solved. Gene therapy
can be divided into two general approaches: those using direct transfer into cells in vivo
and those using indirect methods involving the re-implantation of genetically-modified
cells. Indirect transplantation generally complicates a procedure in terms of risk.
difficulty, efficacy, and cost. Direct gene therapy, on the other hand, is likely to be easier
to perform and less risky, and therefore more widely applicable.
Direct gene therapy can be divided into two categories: those involving viral
vectors and those involving plasmid DNA (pDNA) delivery. Direct viral methods include
adenoviral vectors, herpes vectors, and retroviral infection of tumor cells, hepatectomized
liver, endothelial cells, or damaged muscle. Direct plasmid methods include polylysine
conjugates, liposomes, cationic lipids, the biolistic ‘gun’, and naked DNA. The relative
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merits of the two types of direct gene therapy, viral and plasmid, is under active
investigation as rapid advances are being made in each of the two technologies.
Transgenes within plasmids and viral vectors have been directly expressed in a variety of
rodent tissues, including muscle, lung, brain, liver, and tumor. Adenoviral vectors have
been shown to infect many of these same tissues, but their efficiency and safety in large
species, including primates, need to be further investigated.
Aside from efficiency, plasmid-based vectors appear to offer some advantages
over viral vectors. Some viral vectors, such as herpes virus and adenovirus, may retain
viral genes and promoters that could be expressed in human cells under certain
conditions, causing immune or other adverse effects. On the other hand, humans in
general do not produce anti-DNA antibodies, except in certain diseases such as systemic
lupus erythematosus. Some studies with non-human primates indicate that they do not
produce anti-DNA antibodies, even after repetitive administrations (Wolff, 1997). Viral
vectors are also difficult to scale up for human use, whereas preliminary data indicate that
pDNA can be scaled-up in culture vessels. Improvements in plasmid production in yeast
and purification by column chromotography could further reduce the cost of plasmid
preparation.
Naked DNA gene transfer and therapy (Different ways of injection: i.m., i.v., and
intratumorally)
In our in vivo studies, we administered naked DNA containing the mouse
endostatin gene by intratumoral injection. The parental carrying the gene was pWS4. The
eukaryotic expression vector pWS4 is one of a series vectors first developed by Sheay et
tf/.(1993). It contains a CMV promoter, a polyadenylation sequence and the tripartite
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leader sequence of adenovirus (Avtl) located downstream of the promoter. It has been
demonstrated that the presence of the Avtl fragment can increase gene expression
efficiency up to 18-fold, presumably because mRNA with the regulatory sequence binds
translation initiation factors with greater affinity than do cellular mRNAs (Merrick,
1992). We integrated the mouse endostatin coding sequence into the polylinker site of
pWS4. The new plasmid construct was given the name pXLG-mEndo.
As one of the many forms of gene therapy, “naked” gene transfer has several
advantages over several other approaches (Levy et a/., 1996; Davis et al., 1993). “Naked”
DNA gene transfer strategies do not require dividing cells, have virtually no size
limitation (Yang et al., 1996), and should be less likely to create immunological
problems, since pDNA can be purified to homogeneity and DNA itself is a poor antigen.
Gene expression has been demonstrated by using various reporter genes in different types
of tissues. Studies have shown that in mouse skeletal muscle, which is a very slowly
dividing tissue, plasmid transfer is more efficient than that of adenovirus and retrovirus
vectors (Davis et al, 1993). More recent data have shown that the direct injection of free
pDNA into solid tumors can also result in a high level of transfection (Yang et al., 1996;
Kawase et al., 2003; Nomura et al., 1997). Some studies have demonstrated that cationic
liposomes can enhance the retention of injected DNA in the tumor model, but the cationic
liposome complex does not necessarily improve gene expression because of its poor
dissemination within tumors (Nomura et al., 1997; Nomura et al., 1999). However,
disposition and gene expression characteristics in solid tumors after direct injection of
naked pDNA still remain to be further investigated. In addition, considering clinical
trials, although intratumoral injection has been attempted in lung cancer patients,
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intramuscular and intravascular injection are likely to be more practical for most, if not
all, cancer patients. Surprising successes have been reported with intravenous injection
of naked pDNA in that it accumulates in tissues such as liver and muscle with high
efficiency. The key breakthrough involved the realization that pDNA could be injected
rapidly into blood vessels (using increased volumes) in a manner that facilities
extravasation of the DNA solution outside the blood vessel wall. The extravasation
process places the DNA in contact with the plasma membranes of the underlying
parenchymal cells of the target organ. This intravascular delivery technique, termed
“hydrodynamic delivery”, has become established as the primary non-viral methodology
for delivering pDNA expression constructs to target tissues in vivo (Hagstorm, 2003;
Kobayashi et al., 1997). In conclusion, nonviral gene transfer may become increasingly
important as an alternative delivery method for gene therapy. In future studies, we can
compare different pDNA injection routes such as intramuscular (i.m.) or intravascular
(i.v.) with the intratumoral route used here in order to determine if greater treatment
efficacy can be achieved.
Radiation (y-ray and proton)
Another approach to improve the success of tumor radiotherapy is to reduce the
dose delivered to surrounding normal tissues while increasing the tumor dose. Irradiation
of tumors with protons, instead of y-ray radiation (photons), is an option that is being
used with increasing frequency. The dose distribution along the range of a proton beam
can allow the radiation therapists to reduce the dose delivered to normal tissues by a
factor of 2-5 (Archambeau et al., 1972; Archambeau et al., 1994).
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Protons have excellent physical properties for radiation therapy which permit one
to control very precisely the shape of the dose distribution inside the patient's body. The
dose delivered by a proton beam is well localized in space, not only in the lateral
direction, but also very precisely in depth, due to the presence of the characteristic Bragg
peak (William Bragg, 1862-1942, British physicist). Figure 6.1 shows the dose deposited
in the patient as a function of the depth for a monoenergetic proton beam. This is
compared to the depth dose distribution of a photon beam (the major form of radiation
used for conventional therapy in medical centers with radiotherapy facilities), with the
characteristic exponential decrease of the dose with depth. Through the weighted
superposition of proton beams of different energies (Bragg peaks with different proton
ranges), it is possible to deposit a homogenous dose in the target region using only a
single proton beam direction. The resulting (range-modulated) proton beam distribution
is called Spread Out Bragg Peak (SOBP). Electrons, by comparison, have a diffuse
energy deposition because of multiple, wide-angle scattering. Heavier ions, such as
carbon and neon, have sharper beam edge characteristics than protons, but have
fragmentation events that create range un-sharpness. Thus, proton beams appear to have
an ideal dose distribution characteristic for radiation treatment.
Loma Linda University Medical Center is recognized as a leader in radiation
treatment of cancer through its establishment of the world’s first, largest and most
comprehensive hospital-base proton treatment facility (Slater et al., 1988; Slater et al.,
1991). In the near future, we would like to test the anti-tumor efficacy of proton
treatment in combination with anti-angiogenic therapy.
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Figure 6.1. Physical distribution characteristics of proton and photon
beams. Example of a depth dose distribution for photons and protons: an
unmodulated proton beam (Bragg peak in red), a modulated proton peak (spread
out Bragg peak or SOBP in blue), and a photon beam (in green). The figure shows
that the highest radiation dose delivered using photons occurs close to the point of
entry, whereas the highest dose delivered with protons is at the Bragg peak (or
SOBP).
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Combination Treatment in Cancer Therapy: Radiotherapy, Chemotherapy and
Anti-angiogenic Therapy
The management of cancer has continued to advance with the development of
new chemotherapeutic agents and improved techniques of radiation therapy. Although
new therapeutic approaches have improved survival in cancer patients, each form of
intervention has the potential to produce adverse effects on normal host tissues. The
addition of radiotherapy of the primary tumor to combination chemotherapy has
improved both complete-response rates and survival, but is associated with accentuated
toxicity (Perry et al., 1987; Abid, 2001; Simon et al., 2004). Tumor cells have been
understood to be genetically unstable with an ability to mutate and develop resistance to
chemotherapeutic drugs (Beck et al., 1997). Tumor hypoxia has been considered to be a
potential therapeutic problem because it renders solid tumors more resistant to sparsely
ionizing radiation, as well as many chemotherapeutic drugs (Kizaka-Kondoh, 2003).
Tumor progression and spread depend on tumor vasculature. Anti-angiogenic
therapy targets the tumor vasculature, derived from local or circulating endothelial cells
that are considered genetically stable. Targeting cells that support tumor growth, rather
than cancer cells, is a relatively new approach to cancer therapy that is particularly
promising because these cells are genetically stable, and therefore less likely to
accumulate mutations that allow them to develop drug resistance in a rapid manner. The
enthusiasm felt by many investigators in the field comes from the potential advantages of
such agents compared with standard chemotherapy in treating cancer. These include the
easy access to targets within the vasculature, independence of tumor cell resistance
mechanisms, and the board applicability of this therapy to many tumor types (Folkman,
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1997). Although anti-angiogenic agents offer great therapeutic potential, preclinical and
early clinical trial results suggest that these agents will have a delayed onset of activity
and may induce stabilization of disease, and not regression or cure, in patients with
advanced disease. Studies also suggest that angiogenesis in various capillary beds may be
differentially regulated, thus implying that anti-angiogenic therapy may require organspecific optimization. By combining anti-angiogenic agents with each other and/or with
other modalities used in the treatment of cancer, the limitations of each therapeutic
approach may be overcome, leading to enhanced efficacy with diminished toxicity. In
LLC animal studies, the increase in the response of the primary tumor to
cyclophosphamide, adriamycin, ds-diamminedichloroplatium (II) (CDDP), BCNU
(carmustine), X-rays or 5-fluorouracil and the lung metastases occur to about the same
level with the addition of anti-angiogenic agents to the therapies. With the treatment
combination TNP-470/minocycline/cyclophosphamide 40% of the animals were cured
(Kakeji et al., 1997). The combination of anti-angiogenic therapy (bevacizuma) with
chemotherapy was highly effective in an encouraging, large randomized phase III trial on
metastatic colorectal cancer (Eichhom et al., 2004). As for another conventional cancer
therapy, radiotherapy, the original rationale for combination treatment with radiation and
anti-angiogenic agents was to destroy two separate cell populations: endothelial cells and
cancer cells. My initial ideas for this study also included getting higher expression of
endostatin in the tumor site by using radiotherapy. The results turned out much better
than many investigators originally expected. As for my study, anti-angiogenic agent
endostatin significantly increased the anti-tumor effect of radiation by a factor up to 2.
Agents targeting angiogenesis have been shown to enhance tumor growth delay and
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tissue oxygenation during radiotherapy. Later the additional rationale for anti-angiogenic
therapy: ‘normalizing’ tumor vasculature before its destruction to improve the delivery of
oxygen was proposed by Dr. R.K. Jain in 2001. Recent reports support the premise that
tumor vasculature is quite abnormal and that the endothelial cells that line tumor blood
vessels differ in many respects from normal vasculature (McDonald et al., 2000; St Croix
et al., 2000). Blood vessels within a given tumor are heterogeneous and are subject to
influences by the local microenvironment and cytokines (such as IFN-y, bFGF, and IL-8)
that are produced by tumor cells, macrophages and other cell types (Singh et al., 1996;
Luca et al., 1997). This microenvironment may vary quite extensively when comparing
central areas of a bulky tumor, which maybe hypoxic and necrotic, with more viable
areas toward the periphery (Holash et al., 1999). In this regard, endothelial cells within a
tumor may be heterogeneous with regions of endothelium that are active, immature, and
proliferating in contrast to regions where endothelial cells are quiescent and possibly
even undergoing apoptotic processes (Eberhard et al., 2000; Eatock et al., 2000). The
changes in tumor microenvironment, especially tumor vasculature, are being further
investigated and the anti-tumor mechanisms of anti-angiogenic therapy are also being
exploited to improve the effects of radiotherapy and chemotherapy. Finding new imaging
techniques and surrogate markers that permit quantification of specific vascular changes
during anti-angiogenic therapy may help to refine this theory and to improve the therapy
for solid tumors.
Immune Response: Cancer Immunotherapy
Decreased immune response often observed in cancer patients. The immune
response maybe impair in patients due to the malignancy, and radiation therapy (RT) can
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exacerbate the cancer induced-attenuation of important immune defense mechanisms (Uh
etal, 1994).
It is now generally accepted that tumor immunosurveillance occurs at least to
some extent. The ‘successful’ tumors that emerge in cancer patients have properties that
result in evasion of immune elimination. It is also abundantly evident that both innate and
adaptive immune responses play a role in tumor clearance. Another important point is
that immune recognition of malignant tumors is not unique but involves the same
immunological processes that are used to combat pathogens (Smith, et al., 2001).
Currently the most popular approach to cancer immunotherapy has been the generation of
CD8+ CTL that recognize the tumor antigens in association with MHC class I molecules
on tumor cells. Some data also show that the host’s immune response can potentiate the
anti-tumor effects of anti-angiogenic agents, such as endostatin and angiostatin (Li et al..
2000 and 2001). In our study, we demonstrated that T and B lymphocyte changes
occurred after combined treatment with radiation and anti-angiogenic (pXLG-mEndo)
therapy. Production capacity of Th cell-derived cytokines such as IFN-y and IL-2 also
changed following the treatments. At this time, these experiments were done to obtain
baseline data on changes in immune system status due to our unique treatment approach.
Long-term effects, especially with regard to specific anti-tumor mechanisms, need to be
further investigated to understand and possible exploit the immune response changes
after different treatments.
In addition, some cytokines can act as anti-angiogenic factors. For example, the
interferons (IFNs), pleiotropic cytokines that regulate anti-viral, anti-tumor, apoptotic,
and cellular immune responses, were the first endogenous anti-angiogenic regulators
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identified. In a species-specific manner, IFNs inhibit secretion of such angiogenic factors
as bFGF from tumor cells. It is important to note here that IFN-y is a Thl lymphocytederived cytokine that enhances both innate and adaptive immune mechanisms and that
also has anti-tumor effects.
Taken together, using anti-angiogenic factors that can up-regulate cellular
immune responses in combination with radiotherapy may result in a greater anti-tumor
effect and also provide additional benefits (e.g., lower risk for infection) for patients with
cancer.
Proposed Rationale for Combination Treatment of pXLG-mEndo and
Radiotherapy
In our study, combination treatment with pXLG-mEndo and radiation showed
significantly higher anti-tumor efficacy than either therapy alone. Based on the best
knowledge we have, I proposed the rationales for this project described as below:
1. y-ray irradiation increases gene expression in the tumor sites.
2. y-ray irradiation improves transfection efficiency of plasmid DNA.
3. Anti-angiogenic therapy “normalizes” abnormal tumor vasculature before its
destruction and thus enhances the efficacy of radiation therapy.
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